<SEC-DOCUMENT>0001193125-20-153449.txt : 20200528
<SEC-HEADER>0001193125-20-153449.hdr.sgml : 20200528
<ACCEPTANCE-DATETIME>20200527212930
ACCESSION NUMBER:		0001193125-20-153449
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20200528
DATE AS OF CHANGE:		20200527

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-238730
		FILM NUMBER:		20916776

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d918491d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2" COLOR="#de1a1e"><B>The information in this preliminary prospectus supplement is not complete and may be changed. A
registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities in any
jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-238730 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2" COLOR="#de1a1e"><B>SUBJECT TO COMPLETION, DATED MAY 27, 2020 </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS SUPPLEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(To Prospectus dated May 27, 2020)
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g918491g99y26.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>Common Stock
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are offering
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our common stock is listed on the New York Stock Exchange under the symbol &#147;RCUS.&#148; On May 27, 2020, the last reported sale price
of our common stock was $27.05 per share. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are
an &#147;emerging growth company&#148; under applicable Securities and Exchange Commission rules and are eligible for reduced public company disclosure requirements. See &#147;Prospectus Supplement Summary &#151; Implications of Being an Emerging
Growth Company.&#148; </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Investing in our common stock involves risk. See the
section titled &#147;<A HREF="#suprom812077_3">Risk Factors</A>&#148; beginning on page&nbsp;S-7 of this prospectus supplement. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Neither the U.S. Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities
or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Per Share</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Underwriting discounts and commissions</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Proceeds to us, before expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="1">(1)</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="1">See &#147;Underwriting&#148; for additional information regarding underwriting compensation. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead Sciences, Inc. has indicated an interest in purchasing up to approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of the shares of common stock offered hereby at the price offered to the public. Because this indication of interest is not a binding agreement or commitment to purchase, this entity may elect not to
purchase any shares in this offering, or the underwriters may elect not to sell any shares in this offering to it. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters expect to deliver the shares to purchasers against payment on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020, through the book-entry facilities of The Depository Trust Company. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>SVB Leerink</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Evercore ISI</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Prospectus Supplement dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 </B></FONT></P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS SUPPLEMENT </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_1">About this Prospectus Supplement</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-i</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_2">Prospectus Supplement Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-1</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_3">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-7</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_4">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-9</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_5">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-11</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_6">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-12</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_7">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-13</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_8">Material U.S. Federal Income Tax Considerations For <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-14</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_9">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-18</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_10">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-23</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_11">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-23</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_12">Where You Can Find Additional Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-23</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#suprom812077_13">Incorporation of Certain Information By Reference</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">S-23</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>PROSPECTUS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_1">About this Prospectus</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">i</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_2">Prospectus Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_3">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_4">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_5">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_6">Description of Capital Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_7">Description of Debt Securities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_8">Description of Warrants</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_9">Legal Ownership of Securities</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_10">Plan of Distribution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">26</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_11">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_12">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_13">Where You Can Find Additional Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">28</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2"><A HREF="#toc934781_14">Incorporation of Certain Information By Reference</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:16%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_1"></A>ABOUT THIS
PROSPECTUS&nbsp;SUPPLEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and the
accompanying prospectus dated May 27, 2020, form part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange Commission (&#147;SEC&#148;), utilizing a &#147;shelf&#148;
registration process. Under the shelf registration statement we may, from time to time, offer and sell, either individually or in combination, in one or more offerings in unlimited amounts shares of our common stock, preferred stock, debt securities
and warrants, including common stock or preferred stock upon conversion of debt securities, common stock upon conversion of preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. This document is in two
parts. The first part is this prospectus supplement, which describes the specific terms of this common stock offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference
herein. The second part, the accompanying prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To the extent there is a conflict between the information
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-i
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
contained in this prospectus supplement and the information contained in the accompanying prospectus or any document incorporated by reference therein filed prior to the date of this prospectus
supplement, you should rely on the information in this prospectus supplement; provided that if any statement in one of these documents is inconsistent with a statement in another document having a later date the statement in the document having the
later date modifies or supersedes the earlier statement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have
not, and the underwriters have not, authorized anyone to provide any information other than that contained or incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectus that we have
authorized for use in connection with this offering. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The information contained in this
prospectus supplement, the accompanying prospectus, any free writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference herein or therein is accurate only as of the
respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of our common stock. It is important for you to read and consider all information contained in this prospectus
supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering, including the documents incorporated by reference herein and therein, in making your investment decision. See
the sections titled &#147;Where You Can Find Additional Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement and the accompanying prospectus. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and the underwriters are offering to sell, and seeking offers to buy,
shares of our common stock only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the common stock in certain jurisdictions may be restricted by
law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about, and observe any restrictions relating to, the offering of the common stock and the
distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a
solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and the accompanying prospectus contain and
incorporate by reference market data and industry statistics and forecasts that are based on independent industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the
accuracy or completeness of this information and we have not independently verified this information. Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus supplement, the accompanying
prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk Factors&#148; and elsewhere in
this prospectus supplement, the accompanying prospectus and any related free writing prospectus, and under similar headings in the other documents that are incorporated by reference into this prospectus supplement and the accompanying prospectus.
Accordingly, investors should not place undue reliance on this information. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Except as otherwise indicated herein or as the context otherwise requires, references in this prospectus supplement, the accompanying prospectus and any related free writing prospectus we authorize for
use to &#147;Arcus,&#148; &#147;the company,&#148; &#147;we,&#148; &#147;us,&#148; &#147;our&#148; and similar references refer to Arcus Biosciences, Inc., a corporation under the laws of the State of Delaware, and its wholly owned subsidiaries.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-ii
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_2"></A>PROSPECTUS&nbsp;SUPPLEMENT SUMMARY </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>This summary highlights certain information about us, this offering and
selected information contained elsewhere in or incorporated by reference into this prospectus supplement and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider before
deciding whether to invest in our common stock. For a more complete understanding of our company and this offering, you should read and consider carefully the more detailed information included or incorporated by reference in this prospectus
supplement, the accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering, including the factors described in the section titled &#147;Risk Factors&#148; in this prospectus supplement
beginning on page&nbsp;S-<U></U>7 and our Quarterly Report on Form 10-Q for the three months ended March 31, 2020, along with our consolidated financial statements and notes to those consolidated financial statements and the other information
incorporated by reference in this prospectus supplement and the accompanying prospectus, as well as in any free writing prospectus we have authorized for use in connection with this offering, before making an investment decision. </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Arcus Biosciences, Inc. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are a clinical-stage biopharmaceutical company focused on
creating best-in-class cancer therapies. Our initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. We have built a robust and highly efficient drug discovery capability
designed to create highly differentiated small molecules, which we have the ability to develop in combinations with our monoclonal antibodies through rationally designed, indication-specific, adaptive clinical trial designs. Our vision is to create,
develop and commercialize highly differentiated combination cancer therapies that have the potential to cure. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I></I><B><I>Collaboration with Gilead</I></B><I> </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May 2020, we entered into an Option, License and
Collaboration Agreement with Gilead Sciences, Inc. pursuant to which Gilead will obtain an exclusive option to all of our current and future programs during the <FONT STYLE="white-space:nowrap">10-year</FONT> collaboration term. In connection with
the entering into of this agreement, we and Gilead entered into a Common Stock Purchase Agreement and an Investor Rights Agreement. See &#147;Recent Developments&#148; below for a description of these agreements. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-1
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Our Clinical Development Pipeline </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following chart summarizes our clinical pipeline. We
hold worldwide development and commercialization rights to all our investigational products with the exception of zimberelimab, for which we hold rights outside of China and Thailand. Taiho Pharmaceutical Co., Ltd. (Taiho) has a time-limited option
to exclusively license the development and commercialization rights to each of our programs for Japan and certain other territories in Asia (excluding China), which they have exercised with respect to our adenosine receptor antagonist program
(including AB928) and our anti-PD-1 program (including zimberelimab). </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g918491g31a51.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently have four
clinical-stage investigational products, the profiles of which are summarized below: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AB928</B><I>,</I><B><I> </I></B>the first and only dual A2a/A2b<I> </I>adenosine receptor antagonist in the clinic, is designed to maximally inhibit
the adenosine-driven impairment of tumor-infiltrating lymphocytes (mainly T&nbsp;cells and NK cells) and myeloid cells (dendritic cells, macrophages), mediated by the A2a and A2b receptors, respectively. A2b is also upregulated in certain tumors,
such as in KRAS-mutated cancers. As a result, AB928 may uniquely block adenosine&#146;s immunosuppressive and cancer cell-intrinsic effects. Developed specifically for the oncology setting, AB928 achieves high penetration of tumor tissue, robust
potency in the presence of high adenosine concentrations, and minimal shift in potency from non-specific plasma protein binding. AB928 has demonstrated a favorable safety profile with a variety of combination regimens and exhibits
pharmacokinetics/pharmacodynamics consistent with once-daily dosing. AB928 is currently being evaluated by us in several Phase&nbsp;1b/2 studies across multiple indications. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AB154</B> is our in-licensed anti-TIGIT monoclonal antibody designed to promote sustained immune activation and tumor clearance in combination with
proven immunotherapy strategies. TIGIT-mediated signaling is known to suppress an array of anti-cancer immune cells and has been associated with poor prognosis in a variety of tumor types. AB154 blocks TIGIT with sub-nanomolar affinity and, in a
Phase&nbsp;1 trial, demonstrated complete receptor coverage on all TIGIT-expressing peripheral leukocytes. AB154 exhibited a favorable safety profile in the Phase 1 trial and is currently in randomized Phase&nbsp;2 development for the treatment of
first-line metastatic non-small cell lung cancer in combination with zimberelimab (previously referred to as AB122; an anti-PD-1 antibody) and AB928 (a dual A2a/A2b adenosine receptor antagonist). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Zimberelimab (</B><B>previously referred to as</B><B> AB122).</B><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>We in-licensed<B> </B>zimberelimab, an anti-PD-1
monoclonal antibody, to enable the development of precision combination regimens with full line-of-sight </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-2
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
to the commercialization of innovative therapies for all patients who may benefit. Data from clinical studies with zimberelimab conducted by us and data presented by Gloria Biosciences from their
clinical trial conducted independently from us demonstrate clinical activity and a safety profile that are consistent with those of currently approved anti-PD-1 therapies. The most advanced study being conducted by us with zimberelimab is a
randomized Phase&nbsp;2 study for the treatment of first-line metastatic non-small cell lung cancer, evaluating zimberelimab in combination with AB154, with or without AB928. Zimberelimab is also being evaluated by us in combination with other
agents across several other tumor indications, as well as a monotherapy in a tumor-agnostic, biomarker-selected Phase 1b trial. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AB680</B><B> </B>is an extremely&nbsp;potent and selective small-molecule CD73 inhibitor designed to provide differential benefits relative to
monoclonal antibodies, such as greater inhibition of CD73 enzymatic activity (both soluble and cell-bound) and deeper tumor penetration. CD73 is the primary enzymatic producer of immunosuppressive adenosine in the tumor microenvironment; high CD73
expression is&nbsp;associated with significantly poorer prognosis in several tumor types.&nbsp;By effectively eliminating CD73-derived adenosine, AB680 may improve the efficacy of treatment&nbsp;approaches&nbsp;proven to elicit anti-cancer immune
responses (e.g.,&nbsp;with anti-PD1 and/or platinum-based chemotherapy). AB680 is the first small-molecule CD73 inhibitor in the clinic and demonstrated a favorable safety profile with a long half-life in a Phase 1 trial in healthy volunteers. AB680
is currently in a Phase&nbsp;1/1b study for the treatment of first-line metastatic pancreatic cancer. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Recent Developments </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On May 27, 2020, we entered into an Option, License and Collaboration Agreement, which we refer to as the Collaboration Agreement, with
Gilead Sciences, Inc. pursuant to which Gilead will obtain an exclusive option to acquire an exclusive license to all of our current and future clinical programs during the 10-year collaboration term and, for those programs that enter clinical
development prior to the end of the collaboration term, for up to an additional three years thereafter. Gilead may exercise its option, on a program-by-program basis, upon payment of an option fee that ranges from $200 million to $275 million per
program for our current clinical programs, and $150 million per program for all of our other programs that enter clinical development. If Gilead exercises its option with respect to our TIGIT program, we are also eligible to receive up to
$500&nbsp;million in potential U.S. regulatory approval milestones with respect to AB154. Pursuant to the Collaboration Agreement, Gilead will make a $175 million upfront cash payment and will immediately obtain an exclusive license to our
zimberelimab program. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Upon Gilead&#146;s exercise
of its option to a program, the companies will co-develop, equally share global development costs and equally share all profits and losses for the United States, subject to certain opt-out rights for us, expense caps on our spending and true-up
adjustments. For each optioned program, provided we have not exercised our opt-out rights, we have an option to co-promote in the United States. Gilead will obtain rights to exclusively commercialize any optioned programs outside of the U.S.,
subject to the rights of our existing partners to any territories, and Gilead will pay to us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. Gilead will further provide ongoing research and development
support of up to $400&nbsp;million over the collaboration term. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The Collaboration Agreement is subject to termination by either party for the other party&#146;s uncured material breach or insolvency, and by Gilead with sufficient prior written notice. Other customary
termination rights are further provided in the Collaboration Agreement. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition to the Collaboration Agreement, we and Gilead entered into a Common Stock Purchase Agreement and an Investor Rights Agreement, which we refer to as the Equity Agreements, pursuant to which
Gilead will make an upfront equity investment of $200 million by purchasing from us 5,963,029 shares of our </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-3
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
common stock at a purchase price of $33.54 per share. Gilead also has the right, at its option, to purchase additional shares from us, up to a maximum of 35% of our then-outstanding voting common
stock, from time to time over the next five years, at a purchase price equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) at the time Gilead exercises such option, and the $33.54 initial purchase
price. The Equity Agreements also include a three-year standstill and a two-year lockup and provide Gilead with registration rights commencing at the end of the lockup period, pro rata participation rights in certain future financings and the right
to designate two individuals to be appointed to our Board of Directors. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This transaction is subject to review under the Hart-Scott Rodino Antitrust Improvements Act and other customary closing conditions. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Risks Associated with our Business </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our business is subject to numerous risks. You should read these risks before you invest in our common stock. In particular, our risks
include, but are not limited to, the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">The impact of the COVID-19 pandemic and related risks could have a material adverse impact on our research and development programs and financial
condition; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are early in our development efforts. If we are unable to develop, obtain regulatory approval for and commercialize our investigational products, or
experience significant delays in doing so, our business will be materially harmed; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Clinical drug development is a lengthy, expensive and uncertain process. The results of preclinical studies and early clinical trials are not always
predictive of future results. Any investigational product that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enrollment and retention of subjects in clinical trials is expensive and time consuming, can be made more difficult or rendered impossible by competing
treatments, clinical trials of competing investigational products, and COVID-19 and other public health epidemics, each of which could result in significant delays and additional costs in our product development activities, or in the failure of such
activities; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">If we do not achieve our product development goals in the time frames we announce and expect, the commercialization of our investigational products may
be delayed, our share price may decline and our commercial prospects may be adversely affected; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject to audit and verification procedures
that could result in material changes in the final data and may change as more patient data become available; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Serious adverse events, undesirable side effects or other unexpected properties of our investigational products may be identified during development or
after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our investigational products or, if discovered
following marketing approval, revocation of marketing authorizations or subsequent limitations on the use of our investigational products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies. If these third parties do not
satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and prospects;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">We are currently party to several in-license agreements under which we acquired rights to use, develop, manufacture and/or commercialize certain of our
investigational products. If we breach our obligations </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-4
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="6%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:Times New Roman" SIZE="2">
under these agreements, we may be required to pay damages, lose our rights to these investigational products or both, which would adversely affect our business and prospects; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we expect to depend on our collaboration with Gilead for the research, development, manufacture and commercialization of our investigational products.
If this collaboration is not successful, our business could be adversely affected. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>Implications of Being an Emerging Growth Company </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An
emerging growth company may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes Oxley Act of 2002, or the Sarbanes Oxley
Act; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm
rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">reduced disclosure obligations about our executive compensation arrangements in our periodic reports, proxy statements and registration statements; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">exemptions from the requirements <FONT STYLE="white-space:nowrap">of&nbsp;holding&nbsp;non-binding&nbsp;advisory&nbsp;votes</FONT> on executive
compensation or golden parachute arrangements. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We may take advantage of these provisions until December&nbsp;31, 2023, or such earlier time that we no longer qualify as an emerging growth company. We may choose to take advantage of some but not all of
these reduced reporting burdens. We would cease to be an emerging growth company if we have more than $1.07&nbsp;billion in annual gross revenue, have more than $700&nbsp;million in market value of our capital stock held by non-affiliates or issue
more than $1.0 billion of non-convertible debt over a three-year period. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have elected to avail
ourselves of the extended transition period for complying with new or revised financial accounting standards. As a result of the accounting standards election, we will not be subject to the same implementation timing for new or revised accounting
standards as other public companies that are not emerging growth companies which may make comparison of our financials to those of other public companies more difficult. Additionally, because we have taken advantage of certain reduced reporting
requirements, the information contained or incorporated by reference herein may be different from the information you receive from other public companies in which you hold stock. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Corporate Information </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We were incorporated in Delaware on April&nbsp;30, 2015. Our
principal executive offices are located at 3928 Point Eden Way, Hayward, CA 94545, and our telephone <FONT STYLE="white-space:nowrap">number&nbsp;is&nbsp;(510)&nbsp;694-6200.&nbsp;Our&nbsp;website</FONT> address is www.arcusbio.com. The information
on, or that can be accessed through, our website is not part of this prospectus. We have included our website address as an inactive textual reference only. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arcus Biosciences and the Arcus Biosciences logo are the property of Arcus. Trade names, trademarks and service marks of other companies
appearing in this prospectus are the property of their respective holders. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-5
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>The Offering </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock offered by us </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Option to purchase additional common stock </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted the underwriters an option for a period of 30 days from the date of this prospectus supplement to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock to be outstanding immediately after this offering </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Use of proceeds </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that the net proceeds to us from this offering, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise in
full their option to purchase additional shares of common stock. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">We<B></B>&nbsp;currently intend to use the net proceeds from this offering to fund our research and development activities, for working capital, capital expenditures
and other general corporate purposes. See &#147;Use of Proceeds&#148; on page&nbsp;S-11 of this prospectus supplement. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Risk factors </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Investing in our common stock involves significant risks. See &#147;Risk Factors&#148; beginning on page&nbsp;S-7<B></B>&nbsp;of this prospectus supplement and in our Quarterly Report on Form
10-Q for the three months ended March&nbsp;31, 2020. </FONT></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-top:0px;margin-bottom:1px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:Times New Roman" SIZE="2">New York Stock Exchange trading symbol </FONT></P></TD>
<TD><FONT STYLE="font-family:Times New Roman" SIZE="2">Our shares of common stock are listed on the New York Stock Exchange under the symbol &#147;RCUS.&#148; </FONT></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of common stock to be outstanding after
the offering is based on the number of shares outstanding as of March&nbsp;31, 2020. As of that date, we had 45,982,788 shares of common stock outstanding, excluding: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,725,835 shares of common stock underlying options outstanding at a weighted average exercise price of $9.74&nbsp;per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,505,989&nbsp;shares of common stock available for future grant of equity awards under our equity incentive plans, including our employee stock
purchase plan. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Unless otherwise
indicated, all information in this prospectus supplement assumes: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no exercise of the outstanding options described above; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no issuance of the shares to be issued to Gilead pursuant to the common stock purchase agreement between us and Gilead; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">no exercise by the underwriters of their option to purchase up to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional
shares of our common stock. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-6
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_3"></A>RISK&nbsp;FACTORS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Investing in our common stock involves a high degree of
risk. You should carefully consider the risk factors described below and the risk factors incorporated by reference from our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the three months ended March 31, 2020, and all
other information contained or incorporated by reference in this prospectus supplement and the accompanying prospectus, including our financial statements and the related notes, as may be updated by our subsequent filings under the Securities
Exchange Act of 1934, as amended (&#147;Exchange Act&#148;) and in any free writing prospectus that we have authorized for use in connection with this offering before acquiring shares of our common stock. These risks could have a material and
adverse impact on our business, results of operations, financial condition and growth prospects, which may cause the trading price of our common stock to decline and you could lose all or part of your investment. </I></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Risks related to this offering </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Management will have broad discretion as to the use of
the proceeds from this offering, and we may not use the proceeds effectively. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Our management will have broad discretion in the application of the net proceeds from this offering, and could spend the proceeds in ways that do not improve our results of operations or enhance the value
of our common stock. Our failure to apply these funds effectively could have a material adverse effect on our business and cause the price of our common stock to decline. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>If you purchase shares of common stock in this
offering, you will experience immediate dilution in your investment. You will experience further dilution if we issue additional equity securities in future fundraising transactions. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchasers of common stock in this offering will pay a price per share in this offering that exceeds the net
tangible book value per share of our common stock. Assuming that an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock are sold at a public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, for aggregate net proceeds of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us, if you purchase shares of our common stock in this offering, you will experience immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share,
representing the difference between the public offering price and our as adjusted net tangible book value per share as of March 31, 2020, after giving effect to this offering. See the section below titled &#147;Dilution&#148; for a more detailed
illustration of the dilution you would incur if you purchase common stock in this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B><I>You may experience further dilution if we issue additional equity securities in future fundraising transactions. </I></B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To raise additional capital, we may in the future offer
additional shares of our common stock or other securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. For example, we have agreed to sell Gilead $200 million of
shares of our common stock at a price of $33.54 per share. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or
other securities in the future could have rights superior to existing stockholders. Gilead has been granted an option to purchase up to 35% of our common stock over the next five years at a purchase price equal to the greater of $33.54 per share and
a 20% premium to the trading price of our common stock at the time of purchase. The price per share at which we sell additional shares of our common stock, or securities convertible or exchangeable into common stock, in future transactions may be
higher or lower than the price per share paid by investors in this offering. Further, we have a significant number of stock options outstanding. The exercise of outstanding stock options may result in further dilution of your investment. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-7
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>We expect to depend on our collaboration with Gilead for the research, development, manufacture and
commercialization of our investigational products. If this collaboration is not successful, our business could be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In May 2020, we entered into an option, license and collaboration agreement with Gilead pursuant to which Gilead will obtain an exclusive
option to all of our current and future programs during the 10-year collaboration term. In connection with the entering into of this agreement, we and Gilead also entered into a common stock purchase agreement and an investor rights agreement. Our
agreements with Gilead pose a number of risks including, but not limited to, the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we may not be successful in this collaboration due to various factors, including our ability to demonstrate proof of concept in one or more clinical
studies so that Gilead will exercise its option to these programs; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">if our collaborations on research and development candidates do not result in the successful development and commercialization of products or if Gilead
terminates the collaboration agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our
investigational products could be delayed and we may need additional resources to develop our investigational products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">conflicts may arise between us and Gilead, such as conflicts regarding the combinations or indications to pursue or concerning the interpretation of
clinical data, the commercial potential of any optioned investigational products, the interpretation of financial provisions or the ownership of intellectual property developed during the collaboration. Any such conflicts could slow or prevent the
development or commercialization of our investigational products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">we will be heavily dependent on Gilead for its further development and commercialization of the investigational products from the programs that it opts
into; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead will have the right to designate two individuals to be appointed to our board of directors, will purchase from us about 11.5% of our outstanding
common stock and will have the right (but not the obligation) to acquire from us a total of up to 35% of our outstanding common stock and, as a result, would be able to exert significant influence over our company; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Gilead could independently develop, or develop with third parties, products that compete directly or indirectly with our investigational products if
Gilead believes that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">because Gilead will have an option to all of our programs, it will be difficult for us to enter into new collaborations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, the effectiveness of the collaboration agreement
and the obligations under the other agreements are subject to antitrust authority review and other closing conditions, and if antitrust authorities object to these agreements or if other closing conditions are not satisfied then these agreements may
terminate and we would not receive the benefits of these agreements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-8
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_4"></A>SPECIAL NOTE&nbsp;REGARDING FORWARD-LOOKING STATEMENTS
</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and accompanying
prospectus, and the documents we have filed with the SEC that are incorporated herein by reference, contain &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities
Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, or the Exchange Act. These statements relate to future events or to our future operating or financial performance and involve known and unknown risks, uncertainties and other factors
which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are
not limited to, statements about: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding our relationship with Gilead; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the uses of the net proceeds from the sale of our common stock in this offering; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the length of time our current cash, cash equivalents and short-term investments will be sufficient to fund our planned
clinical development and discovery programs and other capital requirements; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the timing and achievement of our investigational product development activities and ongoing and planned clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations for reporting data from clinical trials in certain timeframes; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to develop intra-portfolio combinations and highly-differentiated small-molecule investigational products, including our ability to create
small-molecule investigational products with ideal pharmacological properties and desired clinical effects; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the efficiency and speed with which we can create and advance small-molecule investigational products and develop our
investigational products and combination therapies; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our reliance on third parties to conduct our ongoing and future clinical trials and third-party manufacturers to manufacture and supply our
investigational products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the nature of the immuno-oncology pathways we are targeting, the size of the potential patient population and the potential
market size; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to obtain and maintain control of our combination investigational products and maximize the commercial potential of our investigational
products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to obtain and maintain regulatory approvals of our investigational products, the potential market opportunities for commercializing our
investigational products; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to retain and recruit key personnel, estimates of our expenses, future revenue, capital requirements and our needs for additional
financing; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to develop, acquire and advance investigational products into, and successfully complete, clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our initiation, timing, progress and results of future research and development programs, preclinical studies and clinical trials;
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our ability to obtain and maintain intellectual property rights covering our investigational products; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding the developments and projections relating to our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations as to the effect that the COVID-19 pandemic will have on our company; and </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our expectations regarding our industry. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148;
&#147;could,&#148; &#147;would,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;project,&#148; &#147;predict,&#148; &#147;potential&#148; and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-9
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks
and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss in greater detail many of these risks and uncertainties under the heading &#147;Risk Factors&#148; contained in this
prospectus supplement and accompanying prospectus and in our most recent Quarterly Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q&nbsp;for</FONT> the quarter ended March 31, 2020, as updated or superseded by the risks and uncertainties
described under similar headings in our subsequent filings under the Exchange Act, each of which is incorporated by reference into this prospectus supplement and accompanying prospectus in their entirety. Also, these forward-looking statements
represent our estimates and assumptions only as of the date of the document containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or
future events or developments. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus supplement and accompanying
prospectus together with the documents we have filed with the SEC that are incorporated by reference and any free writing prospectus that we may authorize for use in connection with this offering completely and with the understanding that our actual
future results may be materially different from what we expect. We qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In addition, statements that &#147;we believe&#148; and
similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus supplement, and while we believe such information forms a reasonable basis for
such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are
inherently uncertain and investors are cautioned not to unduly rely upon these statements. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-10
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_5"></A>USE&nbsp;OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that we will receive net proceeds from the sale
of common stock in this offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us. If the underwriters exercise in full their option to purchase additional common stock, we estimate that the net proceeds to us will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%;padding-bottom:0px; "><FONT STYLE="font-family:Times New Roman" SIZE="2">We currently intend to use the net
proceeds from this offering: to advance our ongoing clinical development programs for AB928, our dual antagonist of the
A</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">2a</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> and A</FONT><FONT
STYLE="font-family:Times New Roman" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">2b</SUB></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> adenosine receptors, AB680, our small-molecule CD73 inhibitor,
zimberelimab, our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> antibody, and AB154, our anti-TIGIT antibody; to fund our ongoing discovery research programs, including
<FONT STYLE="white-space:nowrap">HIF-2</FONT><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT>, which interferes with tumor pseudo-hypoxia; and for working capital and general corporate purposes. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our expected use of the net proceeds from this offering represents our current intentions based upon our
present plans and business conditions. The amounts and timing of our actual use of net proceeds will vary depending on numerous factors and any unforeseen delays or cash needs. As a result, our management will have broad discretion in the
application of the net proceeds, and investors will be relying on our judgment regarding the application of the net proceeds from this offering. In addition, we might decide to postpone or not pursue our planned development activities if the net
proceeds of this offering and our other sources of cash are less than, or do not last as long as, expected. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pending their use, we plan to invest the net proceeds from this offering in short- and intermediate-term, interest-bearing obligations,
investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-11
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_6"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Our net tangible book value as of March 31, 2020, was
approximately $140.6 million, or $3.06 per share. Net tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of March 31, 2020. Dilution
with respect to net tangible book value per share represents the difference between the amount per share paid by purchasers of shares of common stock in this offering, and the net tangible book value per share of our common stock immediately after
this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">After giving effect to the sale of
our common stock in the aggregate amount of $&nbsp;&nbsp;&nbsp;&nbsp; million at the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and after deducting estimated underwriting discounts and commissions and
estimated offering expenses payable by us, our as adjusted net tangible book value as of March&nbsp;31, 2020 would have been $&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. This
amount represents an immediate increase in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders and an immediate dilution in net tangible book value of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors in this offering. The following table illustrates this dilution on a per share basis: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Net tangible book value per share as of March 31, 2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$3.06</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Increase in net tangible book value per share attributable to investors purchasing our common stock in this
offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">As adjusted net tangible book value per share after giving effect to this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dilution per share to investors purchasing our common stock in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The foregoing discussion and
table do not take into account further dilution to new investors that could occur upon the exercise of the underwriters&#146; option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of common stock within 30 days
of the date of the final prospectus supplement for this offering, or the exercise of other outstanding options having a per share exercise price less than the public offering price per share in this offering. If the underwriters exercise in full
their option to purchase additional shares, our net tangible book value on March 31, 2020, after giving effect to this offering, would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, representing an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to new investors purchasing shares of common stock in this offering and an immediate
increase in net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share to our existing stockholders. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The above discussion and table are based on the number of shares outstanding as of March 31, 2020. As of that date, we had 45,982,788
shares of common stock outstanding, excluding: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,725,835 shares of common stock underlying options outstanding at a weighted average exercise price of $9.74 per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,505,989 shares of common stock available for future grant of equity awards under our equity incentive plans, including our employee stock purchase
plan. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-12
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_7"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table sets forth our cash, cash equivalents and
short-term investments and capitalization as of March 31, 2020: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an actual basis; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">on an as adjusted basis to reflect the sale by us of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock in this offering at
the public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">You should read the data set forth in the table below in
conjunction with our financial statements, including the related notes, and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; from our Annual Report on
<FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2019, and Quarterly Report on Form 10-Q for the three months ended March 31, 2020, which are incorporated by reference into this prospectus supplement and
the accompanying prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As&nbsp;of&nbsp;March 31, 2020</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>As<BR>Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom">&nbsp;<FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(unaudited)<BR>(in thousands, except<BR>share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cash, cash equivalents and short-term investments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">157,866</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stockholders&#146; equity:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Preferred stock, $0.0001 par value; 10,000,000 shares authorized, no shares issued and outstanding, actual and as
adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Common stock, $0.0001 par value; 400,000,000 shares authorized, 45,982,788 shares issued and outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">373,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(233,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">(233,079</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Accumulated other comprehensive income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total stockholders&#146; equity</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">140,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">140,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The number of shares of
common stock to be outstanding after the offering is based on the number of shares outstanding as of March 31, 2020. As of that date, we had 45,982,788 shares of common stock outstanding, excluding: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,725,835 shares of common stock underlying options outstanding at a weighted average exercise price of $9.74 per share; and
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">6,505,989 shares of common stock available for future grant of equity awards under our equity incentive plans, including our employee stock purchase
plan. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-13
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_8"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS <FONT
STYLE="white-space:nowrap">FOR&nbsp;NON-U.S.&nbsp;HOLDERS</FONT> </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The following summary describes the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our common stock acquired in this offering
<FONT STYLE="white-space:nowrap">by&nbsp;Non-U.S.&nbsp;Holders</FONT> (as defined below). This discussion is not a complete analysis of all potential U.S. federal income tax consequences relating thereto, and does not deal with foreign, state and
local consequences that may be relevant <FONT STYLE="white-space:nowrap">to&nbsp;Non-U.S.&nbsp;Holders</FONT> in light of their particular circumstances, nor does it address U.S. federal tax consequences (such as gift and estate taxes) other than
income taxes. Special rules different from those described below may apply to <FONT STYLE="white-space:nowrap">certain&nbsp;Non-U.S.&nbsp;Holders</FONT> that are subject to special treatment under the Internal Revenue Code of 1986, as amended (the
Code), such as financial institutions, insurance <FONT STYLE="white-space:nowrap">companies,&nbsp;tax-exempt&nbsp;organizations,&nbsp;broker-dealers&nbsp;and</FONT> traders in securities, certain former U.S. citizens or long-term residents,
&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; corporations that accumulate earnings to avoid U.S. federal income tax, corporations organized outside of the United States, any state thereof or the
District of Columbia that are nonetheless treated as United States income taxpayers for United States federal tax purposes, persons that hold our common stock as part of a &#147;straddle,&#148; &#147;hedge,&#148; &#147;conversion transaction,&#148;
&#147;synthetic security&#148; or integrated investment or other risk reduction strategy, persons who acquire our common stock through the exercise of an option or otherwise as compensation, persons subject to the alternative minimum tax or federal
Medicare contribution tax on net investment income, &#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds, partnerships and
other&nbsp;pass-through&nbsp;entities or arrangements, and investors in such pass-through&nbsp;entities or arrangements. <FONT STYLE="white-space:nowrap">Such&nbsp;Non-U.S.&nbsp;Holders</FONT> are urged to consult their own tax advisors to determine
the U.S. federal, state, local and other tax consequences that may be relevant to them. Furthermore, the discussion below is based upon the provisions of the Code, and Treasury regulations, rulings and judicial decisions thereunder as of the date
hereof, and such authorities may be repealed, revoked or modified, perhaps retroactively, so as to result in U.S. federal income tax consequences different from those discussed below. We have not requested a ruling from the U.S. Internal Revenue
Service (IRS) with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS will agree with such statements and conclusions. This discussion assumes that <FONT
STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> holds our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Persons considering the purchase of our common stock pursuant
to this offering should consult their own tax advisors concerning the U.S. federal income, estate and other tax consequences of acquiring, owning and disposing of our common stock in light of their particular situations as well as any consequences
arising under the laws of any other taxing jurisdiction, including any state, local or foreign tax consequences. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purposes of this discussion, <FONT STYLE="white-space:nowrap">a&nbsp;&#147;Non-U.S.&nbsp;Holder&#148;</FONT> is, for U.S. federal
income tax purposes, a beneficial owner of common stock that is neither a U.S. Holder, nor a partnership (or other entity treated as a partnership for U.S. federal income tax purposes regardless of its place of organization or formation). A
&#147;U.S. Holder&#148; means a beneficial owner of our common stock that is for U.S. federal income tax purposes any of the following: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation or other entity treated as a corporation for U.S. federal income tax purposes created or organized in or under the laws of the U.S., any
state thereof or the District of Columbia; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">an estate the income of which is subject to U.S. federal income taxation regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust if it (1)&nbsp;is subject to the primary supervision of a court within the U.S. and one or more U.S. persons have the authority to control all
substantial decisions of the trust or (2)&nbsp;has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In the case of a holder of our common stock that is classified as a
partnership for U.S. federal income tax </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">purposes, the tax treatment of a person treated as a partner in such partnership for U.S. federal
income tax purposes generally will depend on the status of the partner, the activities of the partner and the partnership and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-14
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
certain determinations made at the partner level. A person treated as a partner in a partnership or who holds our common stock through another transparent entity should consult his, her or its
own tax advisor regarding the tax consequences of the ownership and disposition of our common stock through a partnership or other transparent entity, as applicable.<B> </B> </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Distributions </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distributions, if any, made on our common stock to <FONT
STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> to the extent treated as made out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles) generally will constitute dividends for U.S.
tax purposes and will be subject to withholding tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty, subject to the discussion below regarding foreign accounts. To obtain a reduced rate of withholding under a
treaty, <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> generally will be required to provide us with a properly executed <FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN&nbsp;(in</FONT> the case of individuals) or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN-E&nbsp;(in</FONT></FONT> the case of entities), or other appropriate form, including a U.S. taxpayer identification number, or in certain circumstances, a foreign
tax identifying number, and certifying <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> entitlement to benefits under that treaty. This certification must be provided to us or our paying agent prior to the payment of
dividends and must be updated periodically. In the case of <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> that is an entity, Treasury Regulations and the relevant tax treaty provide rules to determine whether, for purposes of
determining the applicability of a tax treaty, dividends will be treated as paid to the entity or to those holding an interest in that entity. If <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> holds stock through a financial
institution or other agent acting on the holder&#146;s behalf, the holder will be required to provide appropriate documentation to such agent. The holder&#146;s agent will then be required to provide certification to us or our paying agent, either
directly or through other intermediaries. If you are eligible for a reduced rate of U.S. federal withholding tax under an income tax treaty and you do not timely file the required certification, you may be able to obtain a refund or credit of any
excess amounts withheld by timely filing an appropriate claim for a refund with the IRS. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We generally are not required to withhold tax on dividends paid to <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> that are effectively connected with
<FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.Holder&#146;s</FONT> conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, are attributable to a permanent establishment that such holder
maintains in the United States) if a properly executed <FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8ECI,&nbsp;stating</FONT> that the dividends are so connected, is furnished to us (or, if stock is held through a financial institution or
other agent, to such agent) prior to the payment of such dividends. In general, such effectively connected dividends will be subject to U.S. federal income tax, on a net income basis at the regular graduated rates applicable to U.S. residents. A <FONT
STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holder</FONT> receiving effectively connected dividends may also be subject to an additional &#147;branch profits tax,&#148; which is imposed, under certain circumstances, at a rate of 30% (or
such lower rate as may be specified by an applicable treaty) on the <FONT STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> effectively connected earnings and profits, subject to certain
<FONT STYLE="white-space:nowrap">adjustments.&nbsp;Non-U.S.&nbsp;Holders</FONT> should consult their tax advisors regarding any applicable income tax treaties that may provide for different rules. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent distributions on our common stock, if any,
exceed our current and accumulated earnings and profits, they will first reduce <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder&#146;s</FONT> adjusted basis in our common stock, but not below zero, and then will be treated as gain to
the extent of any excess, and taxed in the same manner as gain realized from a sale or other disposition of common stock as described in the next section. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Gain on Disposition of Our Common Stock </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Subject to the discussion below regarding backup withholding and foreign accounts,
<FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> generally will not be subject to U.S. federal income tax with respect to gain realized on a sale or other disposition of our common stock unless (a)&nbsp;the gain is effectively
connected with a trade or business of such holder in the United States (and, if required by an applicable income tax treaty, is attributable to a permanent establishment that such holder maintains in the United States),
(b)&nbsp;the&nbsp;Non-U.S.&nbsp;Holder is a nonresident alien individual and is present in the United States for 183 or more days in the taxable year of the disposition and certain other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-15
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
conditions are met or (c)&nbsp;we are or have been a &#147;United States real property holding corporation&#148; within the meaning of Code Section&nbsp;897(c)(2) at any time within the shorter
of the&nbsp;five-year&nbsp;period preceding such disposition or such holder&#146;s holding period. In general, we would be a U.S. real property holding corporation if interests in U.S. real estate comprise (by fair market value) at least half of our
business assets. We believe that we have not been and we are not, and do not anticipate becoming, a U.S. real property holding corporation. Even if we are treated as a U.S. real property holding corporation, gain realized by <FONT
STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> on a disposition of our common stock will not be subject to U.S. federal income tax so long as <FONT STYLE="white-space:nowrap">(1)&nbsp;the&nbsp;Non-U.S.&nbsp;Holder</FONT> owned,
directly, indirectly and constructively, no more than five percent of our common stock at all times within the shorter of (i)&nbsp;the&nbsp;five-year&nbsp;period preceding the disposition or (ii)&nbsp;the holder&#146;s holding period and
(2)&nbsp;our common stock is regularly traded on an established securities market. There can be no assurance that our common stock will continue to qualify as regularly traded on an established securities market. If any gain on your disposition is
taxable because we are a United States real property holding corporation and your ownership of our common stock exceeds five percent, you will be taxed on such disposition generally in the manner applicable to U.S. persons. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">If you are
<FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> described in (a)&nbsp;above, you will be required to pay tax on the net gain derived from the sale at regular U.S. federal income tax rates, and
<FONT STYLE="white-space:nowrap">corporate&nbsp;Non-U.S.&nbsp;Holders</FONT> described in (a)&nbsp;above may be subject to the additional branch profits tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty.
Gain described in (b)&nbsp;above will be subject to U.S. federal income tax at a flat 30% rate or such lower rate as may be specified by an applicable income tax treaty, which gain may be offset by certain&nbsp;U.S.-source&nbsp;capital losses (even
though you are not considered a resident of the U.S.), provided that <FONT STYLE="white-space:nowrap">the&nbsp;Non-U.S.&nbsp;Holder</FONT> has timely filed U.S. federal income tax returns with respect to such losses. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Information Reporting Requirements and Backup Withholding </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Generally, we must report information to the IRS with
respect to any distributions we pay on our common stock (even if the payments are exempt from withholding), including the amount of any such distributions, the name and address of the recipient, and the amount, if any, of tax withheld. A similar
report is sent to the holder to whom any such distributions are paid. Pursuant to tax treaties or certain other agreements, the IRS may make its reports available to tax authorities in the recipient&#146;s country of residence. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Distributions to
<FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> that are classified as dividends paid by us (or our paying agents) may also be subject to U.S. backup withholding. U.S. backup withholding generally will not apply to <FONT
STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> who provides a properly executed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN,&nbsp;IRS&nbsp;Form&nbsp;W-8BEN-E,&nbsp;or</FONT></FONT></FONT>
<FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-ECI,&nbsp;or</FONT> otherwise establishes an exemption. Notwithstanding the foregoing, backup withholding may apply if the payor has actual knowledge, or reason to know, that the holder is a U.S.
person who is not an exempt recipient. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">U.S.
information reporting and backup withholding requirements generally will apply to the proceeds of a disposition of our common stock effected by or through a U.S. office of any broker, U.S. or foreign, except that information reporting and such
requirements may be avoided if the holder provides a properly executed <FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN&nbsp;or</FONT>
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8BEN-E&nbsp;or</FONT></FONT> otherwise meets documentary evidence requirements for <FONT STYLE="white-space:nowrap">establishing&nbsp;non-U.S.&nbsp;person</FONT>
status or otherwise establishes an exemption. Generally, U.S. information reporting and backup withholding requirements will not apply to a payment of disposition proceeds to <FONT STYLE="white-space:nowrap">a&nbsp;Non-U.S.&nbsp;Holder</FONT> where
the transaction is effected outside the U.S. through <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;office</FONT> of <FONT STYLE="white-space:nowrap">a&nbsp;non-U.S.&nbsp;broker.</FONT> Information reporting and backup withholding
requirements may, however, apply to a payment of disposition proceeds if the broker has actual knowledge, or reason to know, that the holder is, in fact, a U.S. person. For information reporting purposes, certain brokers with substantial U.S.
ownership or operations will generally be treated in a manner similar to U.S. brokers. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be credited against the tax liability of persons subject to backup withholding, provided that the
required information is timely furnished to the IRS. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-16
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Foreign Accounts </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Sections&nbsp;1471 through 1474 of the Code (commonly
referred to as FATCA) impose a U.S. federal withholding tax of 30% on certain payments, including dividends paid on and the gross proceeds of a disposition of our common stock paid to a foreign financial institution (as specifically defined by
applicable rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities substantial information regarding U.S. account holders of such
institution (which includes certain equity holders of such institution, as well as certain account holders that are foreign entities with U.S. owners). FATCA also generally imposes a federal withholding tax of 30% on certain payments, including
dividends paid on and the gross proceeds of a disposition of our common stock to <FONT STYLE="white-space:nowrap">a&nbsp;non-financial&nbsp;foreign</FONT> entity unless such entity provides the withholding agent with either a certification that it
does not have any substantial direct or indirect U.S. owners or provides information regarding substantial direct and indirect U.S. owners of the entity. An intergovernmental agreement between the United States and an applicable foreign country may
modify those requirements. The withholding tax described above will not apply if the foreign financial institution <FONT STYLE="white-space:nowrap">or&nbsp;non-financial&nbsp;foreign</FONT> entity otherwise qualifies for an exemption from the rules.
Holders are encouraged to consult with their own tax advisors regarding the possible implications of FATCA on their investment in our common stock. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The withholding provisions described above currently apply to payments of dividends. Under recent proposed Treasury Regulations, the
preamble to which states that taxpayers may rely on them, this withholding tax will not apply to payments of gross proceeds from a sale or other disposition of common stock. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>EACH PROSPECTIVE INVESTOR SHOULD CONSULT ITS OWN TAX ADVISOR REGARDING THE
TAX CONSEQUENCES OF PURCHASING, HOLDING AND DISPOSING OF OUR COMMON STOCK, INCLUDING THE CONSEQUENCES OF ANY RECENT CHANGE IN APPLICABLE LAW. </B></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-17
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_9"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc., SVB Leerink LLC and Evercore
Group L.L.C. are acting as joint book-running managers of this offering and as representatives of the underwriters named below. Subject to the terms and conditions stated in the underwriting agreement dated the date of this prospectus supplement,
each underwriter named below has severally agreed to purchase, and we have agreed to sell to that underwriter, the number of shares set forth opposite the underwriter&#146;s name. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Underwriter</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Number<BR>of&nbsp;Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Citigroup Global Markets Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">SVB Leerink LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Evercore Group L.L.C.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriting agreement
provides that the obligations of the underwriters to purchase the shares included in this offering are subject to approval of legal matters by counsel and to other conditions. The underwriters are obligated to purchase all the shares (other than
those covered by the underwriters&#146; option to purchase additional shares described below) if they purchase any of the shares. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set forth on the cover of
this prospectus supplement. Any shares sold by the underwriters to securities dealers may be sold at a discount from the initial public offering price not to exceed $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share.
If all the shares are not sold at the initial offering price, the underwriters may change the offering price and the other selling terms. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus supplement, to purchase up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares at the public offering price less the underwriting discount. To the extent the option is exercised, each
underwriter must purchase a number of additional shares approximately proportionate to that underwriter&#146;s initial purchase commitment. Any shares issued or sold under the option will be issued and sold on the same terms and conditions as the
other shares that are the subject of this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We and our officers and directors have agreed that, subject to specified limited exceptions, for a period of 90 days from the date of this
prospectus supplement, we and they will not, without the prior written consent of Citigroup Global Markets Inc., SVB Leerink LLC and Evercore Group L.L.C., offer, sell, contract to sell, pledge or otherwise dispose of, (or enter into any transaction
which is designed to, or might reasonably be expected to, result in the disposition of), directly or indirectly, or hedge any shares or any securities convertible into or exchangeable for our common stock. Citigroup Global Markets Inc., SVB Leerink
LLC and Evercore Group L.L.C. in their sole discretion may release any of the securities subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time without notice. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares are listed on the New York Stock Exchange under the symbol &#147;RCUS.&#148; </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The following table shows the underwriting discounts and
commissions that we are to pay to the underwriters in connection with this offering. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Paid&nbsp;by&nbsp;Arcus&nbsp;Biosciences,&nbsp;Inc.</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>No&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Full&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:Times New Roman" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We estimate that our total
expenses of this offering, excluding underwriting discounts and commissions, will be approximately $675,000. We have also agreed to reimburse the underwriters for certain expenses incurred by them in connection with this offering in an amount up to
$35,000. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-18
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the offering, the underwriters may purchase and sell shares in the open
market. Purchases and sales in the open market may include short sales, purchases to cover short positions, which may include purchases pursuant to the underwriters&#146; option to purchase additional shares and stabilizing purchases. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Short sales involve secondary market sales by the underwriters of a greater number of shares than they are required to purchase in the offering.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Covered&#148; short sales are sales of shares in an amount up to the number of shares represented by the underwriters&#146; option to purchase
additional shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Naked&#148; short sales are sales of shares in an amount in excess of the number of shares represented by the underwriters&#146; option to
purchase additional shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Covering transactions involve purchases of shares either pursuant to the underwriters&#146; option to purchase additional shares or in the open market
in order to cover short positions. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a naked short position, the underwriters must purchase shares in the open market. A naked short position is more likely to be created if the
underwriters are concerned that there may be downward pressure on the price of the shares in the open market after pricing that could adversely affect investors who purchase in the offering. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">To close a covered short position, the underwriters must purchase shares in the open market or must exercise the option to purchase additional shares.
In determining the source of shares to close the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares
through the underwriters&#146; option to purchase additional shares. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stabilizing transactions involve bids to purchase shares so long as the stabilizing bids do not exceed a specified maximum.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Purchases to cover short
positions and stabilizing purchases, as well as other purchases by the underwriters for their own accounts, may have the effect of preventing or retarding a decline in the market price of the shares. They may also cause the price of the shares to be
higher than the price that would otherwise exist in the open market in the absence of these transactions. The underwriters may conduct these transactions on the New York Stock Exchange, in <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">the&nbsp;over-the-counter&nbsp;market</FONT></FONT> or otherwise. If the underwriters commence any of these transactions, they may discontinue them at any time. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Conflicts of Interest </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The underwriters are full service financial institutions engaged in various activities, which may include securities trading, commercial
and investment banking, financial advisory, investment management, principal investment, hedging, financing and brokerage activities. The underwriters and their respective affiliates have in the past performed commercial banking, investment banking
and advisory services for us from time to time for which they have received customary fees and reimbursement of expenses and may, from time to time, engage in transactions with and perform services for us in the ordinary course of their business for
which they may receive customary fees and reimbursement of expenses. In the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt
and equity securities (or related derivative securities) and financial instruments (which may include bank loans and/or credit default swaps) for their own account and for the accounts of their customers and may at any time hold long and short
positions in such securities and instruments. Such investments and securities activities may involve securities and/or instruments of ours or our affiliates. The underwriters and their affiliates may also make
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-19
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
investment recommendations and/or publish or express independent research views in respect of such securities or financial instruments and may hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the underwriters may be required to make because of
any of those liabilities. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in
the European Economic Area </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In relation to
each member state of the European Economic Area or EEA Member State, no shares have been offered or will be offered pursuant to the offering to the public in that EAA Member State prior to the publication of a prospectus in relation to the shares
which has been approved by the competent authority in that EAA Member State or, where appropriate, approved in another EAA Member State and notified to the competent authority in that EAA Member State, all in accordance with the Prospectus
Regulation, except that an offer to the public in that EEA Member State of any of our shares may be made at any time under the following exemptions under the Prospectus Regulation: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Regulation; </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to fewer than 150, natural or legal persons, other than qualified investors as defined in the Prospectus Regulation, as permitted under the Prospectus
Regulation, subject to obtaining the prior consent of the underwriters or the underwriters nominated by us for any such offer; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">provided that no such offer of shares shall require us or any underwriter to
publish a prospectus pursuant to Article 3 of the Prospectus Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any offer of shares in any EEA Member
State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for the shares and the expression
&#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The sellers of the shares have not authorized and do not authorize the making of any offer of shares through any financial intermediary on their behalf, other than offers made by the underwriters with a
view to the final placement of the shares as contemplated in this prospectus supplement. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further offer of the shares on behalf of the sellers or the
underwriters. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in the United
Kingdom </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and the
accompanying prospectus are only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Regulation that are also (i)&nbsp;investment
professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the &#147;Order&#148;) or (ii)&nbsp;high net worth entities, and other persons to whom it may lawfully be communicated,
falling within Article 49(2)(a) to (d)&nbsp;of the Order (each such person being referred to as a &#147;relevant person&#148;). This prospectus supplement and its contents are confidential and should not be distributed, published or reproduced (in
whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a relevant person should not act or rely on this document or any of its contents. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-20
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in France </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Neither this prospectus supplement nor any other offering material relating to the shares described in this
prospectus supplement has been submitted to the clearance procedures of the<I>&nbsp;Autorit&eacute; des March&eacute;s Financiers</I>&nbsp;or of the competent authority of another member state of the European Economic Area and notified to
the<I>&nbsp;Autorit&eacute; des March&eacute;s Financiers.</I>&nbsp;The shares have not been offered or sold and will not be offered or sold, directly or indirectly, to the public in France. Neither this prospectus supplement nor any other offering
material relating to the shares has been or will be: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">released, issued, distributed or caused to be released, issued or distributed to the public in France; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">used in connection with any offer for subscription or sale of the shares to the public in France. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Such offers, sales and distributions will be made in France
only: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to qualified investors (<I>investisseurs qualifi&eacute;s</I>) and/or to a restricted circle of investors (<I>cercle restreint
d&#146;investisseurs</I>), in each case investing for their own account, all as defined in, and in accordance with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">articles&nbsp;L.411-2,&nbsp;D.411-1,&nbsp;D.411-2,&nbsp;D.734-1,&nbsp;D.744-1,&nbsp;D.754-1&nbsp;and&nbsp;D.764-1&nbsp;
of</FONT></FONT></FONT></FONT></FONT></FONT></FONT> the French<I>&nbsp;Code mon&eacute;taire et financier</I>; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to investment services providers authorized to engage in portfolio management on behalf of third parties; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">in a transaction that, in accordance with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">article&nbsp;L.411-2-II-1&deg;</FONT></FONT></FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">-or-2&deg;</FONT></FONT> <FONT
STYLE="white-space:nowrap">-or&nbsp;3&deg;</FONT> of the French<I>&nbsp;Code mon&eacute;taire et financier</I><I></I>&nbsp;and <FONT STYLE="white-space:nowrap">article&nbsp;211-2&nbsp;of</FONT> the General Regulations (<I>R&egrave;glement
G&eacute;n&eacute;ral</I>) of the<I>&nbsp;Autorit&eacute; des March&eacute;s Financiers</I>, does not constitute a public offer (<I>appel public &agrave; l&#146;&eacute;pargne</I>). </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares may be resold directly or indirectly, only in
compliance with <FONT STYLE="white-space:nowrap">articles&nbsp;L.411-1,</FONT> <FONT STYLE="white-space:nowrap">L.411-2,</FONT> <FONT STYLE="white-space:nowrap">L.412-1</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">and&nbsp;L.621-8&nbsp;through&nbsp;L.621-8-3&nbsp;of</FONT></FONT></FONT> the French<I>&nbsp;Code mon&eacute;taire et financier</I>. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Hong Kong </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute
an offer to the public within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong), or (ii)&nbsp;to &#147;professional investors&#148; within the meaning of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any
rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; within the meaning of the Companies Ordinance (Cap. 32, Laws of Hong Kong) and no advertisement, invitation or document
relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public
in Hong Kong (except if permitted to do so under the laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; within the meaning
of the Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong) and any rules made thereunder. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Japan </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The shares offered in this prospectus supplement have not been and will not be registered under the Financial Instruments and Exchange Law of Japan. The shares have not been offered or sold and will not
be offered or sold, directly or indirectly, in Japan or to or for the account of any resident of Japan (including any corporation or other entity organized under the laws of Japan), except (i)&nbsp;pursuant to an exemption from the registration
requirements of the Financial Instruments and Exchange Law and (ii)&nbsp;in compliance with any other applicable requirements of Japanese law. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Singapore </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus
supplement and any other document or material in connection with the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-21
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for
subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii) to a
relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the
conditions of, any other applicable provision of the SFA, in each case subject to compliance with conditions set forth in the SFA. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and
the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an individual
who is an accredited investor, </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">shares,
debentures and units of shares and debentures of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the
shares pursuant to an offer made under Section&nbsp;275 of the SFA except: </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">to an institutional investor (for corporations, under Section&nbsp;274 of the SFA) or to a relevant person defined in Section&nbsp;275(2) of the SFA,
or to any person pursuant to an offer that is made on terms that such shares, debentures and units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than S$200,000 (or
its equivalent in a foreign currency) for each transaction, whether such amount is to be paid for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions specified in Section&nbsp;275 of
the SFA; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where no consideration is or will be given for the transfer; or </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">where the transfer is by operation of law. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Notice to Prospective Investors in Canada </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The shares offered in this prospectus supplement may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that
are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT
STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption from, or in a transaction not subject
to, the prospectus requirements of applicable securities laws. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto)
contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should
refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pursuant to section 3A.3 (or, in the case of securities
issued or guaranteed by the government of a non-Canadian jurisdiction, section 3A.4) of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105</FONT> Underwriting Conflicts <FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),</FONT> the
representatives are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in connection with this offering. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-22
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_10"></A><A NAME="suprom812077_10"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Cooley LLP will pass upon the validity of the common stock
offered hereby. Gunderson Dettmer Stough Villeneuve Franklin&nbsp;&amp; Hachigian, LLP is representing the underwriters in connection with this offering. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_11"></A><A NAME="suprom812077_11"></A>EXPERTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial
statements included in our Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019, as set forth in their report, which is incorporated by reference in this prospectus supplement and accompanying prospectus and elsewhere in the
registration statement. Our financial statements are incorporated by reference in reliance on Ernst &amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_12"></A><A NAME="suprom812077_12"></A>WHERE YOU&nbsp;CAN FIND ADDITIONAL INFORMATION </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">This prospectus supplement and the accompanying prospectus
are part of the registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3&nbsp;we</FONT> filed with the SEC under the Securities Act and do not contain all the information set forth in the registration statement. Whenever a reference
is made in this prospectus supplement or the accompanying prospectus to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the
exhibits to the reports or other documents incorporated by reference into this prospectus supplement and the accompanying prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting
requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov.
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">We maintain a website at www.arcusbio.com.
Information contained in or accessible through our website does not constitute a part of this prospectus&nbsp;supplement or the accompanying prospectus and is not incorporated by reference into this prospectus supplement or the accompanying
prospectus. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><A NAME="suprom812077_13"></A><A NAME="suprom812077_13"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The SEC allows us to &#147;incorporate by reference&#148;
information from other documents that we file with it, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus
supplement and the accompanying prospectus. Information in this prospectus supplement and the accompanying prospectus supersedes information incorporated by reference that we filed with the SEC prior to the date of this prospectus supplement and the
accompanying prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus supplement and the accompanying prospectus. We incorporate by reference into this prospectus
supplement, the accompanying prospectus and the registration statement of which this prospectus supplement and the accompanying prospectus are a part the information or documents listed below that we have filed with the SEC (Commission File <FONT
STYLE="white-space:nowrap">No.&nbsp;001-38419),</FONT> excluding any portions of any Form <FONT STYLE="white-space:nowrap">8-K</FONT> that are not deemed &#147;filed&#148; pursuant to the General Instructions of
<FONT STYLE="white-space:nowrap">Form&nbsp;8-K:</FONT> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000156459020008972/rcus-10k_20191231.htm"><FONT STYLE="white-space:nowrap">Form&nbsp;10-K
</FONT></A> for the year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;5, 2020; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the information specifically incorporated by reference into our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> for the year ended
December&nbsp;31, 2019, from our proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000156459020017693/rcus-def14a_20200604.htm">Schedule&nbsp;14A</A> filed with the SEC on April&nbsp;21, 2020; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-23
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000156459020021282/rcus-10q_20200331.htm">Form&nbsp;10-Q</A> for the
quarter ended March&nbsp;31, 2020, filed with the SEC on May 5, 2020; </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">our Current Reports on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;
filed</FONT> with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000156459020026867/rcus-8k_20200521.htm">May&nbsp;
26, 2020</A>, and <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000119312520152272/d923203d8k.htm">May&nbsp;27, 2020</A>; and </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:0px;margin-bottom:-6px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">the description of our common stock set forth in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000119312518077572/d461416d8a12b.htm">
<FONT STYLE="white-space:nowrap">Form&nbsp;8-A</FONT></A> filed with the SEC on March&nbsp;9, 2018, including any amendment or report filed for the purpose of updating such description. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">We also incorporate by reference any future filings (other than current
reports furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> and exhibits filed on such form that are related to such items unless such <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT>
expressly provides to the contrary) made with the SEC pursuant to Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act. Information in such future filings updates and supplements the information provided in this prospectus supplement and the
accompanying prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by
reference to the extent that statements in the later filed document modify or replace such earlier statements. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">You can request a copy of these filings, at no cost, by writing or telephoning us at the following address or telephone number: </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Arcus Biosciences, Inc. </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Attn: Corporate Secretary </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">3928 Point Eden Way </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Hayward, CA 94545 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="white-space:nowrap">(510)&nbsp;694-6200.</FONT></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">S-24
</FONT></P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prospectus </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g934781g87f98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to
time, we may offer and sell any combination of the securities described in this prospectus, either individually or in combination. We may also offer common stock or preferred stock upon conversion of debt securities, common stock upon conversion of
preferred stock, or common stock, preferred stock or debt securities upon the exercise of warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide the specific terms of
these offerings and securities in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses to be provided to you in connection with these offerings. The prospectus supplement and any related free
writing prospectus may also add, update or change information contained in this prospectus. You should carefully read this prospectus, the applicable prospectus supplement and any related free writing prospectus, as well as any documents
incorporated by reference, before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the New York Stock Exchange
under the trading symbol &#147;RCUS.&#148;&nbsp;On May&nbsp;26, 2020, the last reported sale price of our common stock was $33.54 per share. The applicable prospectus supplement will contain information, where applicable, as to other listings, if
any, on the New York Stock Exchange or other securities exchange of the securities covered by the applicable prospectus supplement. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in
our securities involves a high degree of risk. Before making an investment decision, you should review carefully the risks described under the heading &#147;<A HREF="#toc934781_3">Risk Factors</A>&#148; on page 6 of this prospectus and any similar
section contained in the applicable prospectus supplement and in any free writing prospectuses we have authorized for use in connection with a specific offering, and under similar headings in the documents that are incorporated by reference into
this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless accompanied by a prospectus supplement.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The securities may be sold directly by us to investors, through agents designated from time to time or to or through underwriters or
dealers, on a continuous or delayed basis. The supplements to this prospectus will provide the specific terms of the plan of distribution. If any agents or underwriters are involved in the sale of any securities with respect to which this prospectus
is being delivered, the names of such agents or underwriters and any applicable fees, commissions, discounts and over-allotment options will be set forth in a prospectus supplement. The price to the public of such securities and the net proceeds we
expect to receive from such sale will also be set forth in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B><I>We are an emerging growth company as that term
is used in the Jumpstart Our Business Startups Act of 2012 and, as such, we have elected to take advantage of certain reduced public company reporting requirements for this prospectus and future filings. </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or
determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus is May 27, 2020 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">i</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_4">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_9">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_10">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_11">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_12">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_13">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toc934781_14">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of an automatic registration statement on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> that we filed with the
Securities and Exchange Commission, or SEC, using a &#147;shelf&#148; registration process as a &#147;well-known seasoned issuer&#148; as defined in Rule 405 under the Securities Act of 1933, as amended, or the Securities Act. Under this shelf
registration statement, we may, from time to time, offer and sell, either individually or in combination, in one or more offerings, any combination of the securities described in this prospectus. There is no limit on the aggregate amount of the
securities that we may offer pursuant to the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with
a general description of the securities we may offer. Each time we offer securities under this prospectus, we will provide a prospectus supplement that will contain more specific information about the terms of that offering. We may also authorize
one or more free writing prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also
add, update or change any of the information contained in this prospectus or in the documents that we have incorporated by reference into this prospectus. We urge you to read carefully this prospectus, any applicable prospectus supplement and any
free writing prospectuses we have authorized for use in connection with a specific offering, together with the information incorporated herein by reference as described under the heading &#147;Incorporation of Certain Information by Reference,&#148;
before buying any of the securities being offered. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>This prospectus may not be used to consummate a sale of securities unless it is
accompanied by a prospectus supplement. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in, or incorporated by reference into, this
prospectus and any applicable prospectus supplement, along with the information contained in any free writing prospectuses we have authorized for use in connection with a specific offering. We have not authorized anyone to provide you with different
or additional information. You should not rely upon any information or representation not contained or incorporated by reference in this prospectus, any applicable prospectus supplement or in any related
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
free writing prospectus that we may authorize to be provided to you. This prospectus is an offer to sell only the securities offered hereby, but only under circumstances and in jurisdictions
where it is lawful to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information appearing in this prospectus, any applicable prospectus supplement or any related free
writing prospectus is accurate only as of the date on the front of the document and any information we have incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of
this prospectus, any applicable prospectus supplement or any related free writing prospectus, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains and incorporates by reference market data and industry statistics and forecasts that are based on independent
industry publications and other publicly available information. Although we believe that these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this information.
Although we are not aware of any misstatements regarding the market and industry data presented in this prospectus and the documents incorporated herein by reference, these estimates involve risks and uncertainties and are subject to change based on
various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated
by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains
summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some
of the documents referred to herein have been filed, will be filed or will be incorporated by reference as exhibits to the registration statement of which this prospectus is a part, and you may obtain copies of those documents as described below
under the section entitled &#147;Where You Can Find Additional Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This summary highlights selected information appearing elsewhere in this prospectus or incorporated by reference in this prospectus, and
does not contain all of the information that you need to consider in making your investment decision. You should carefully read the entire prospectus, the applicable prospectus supplement and any related free writing prospectus, including the risks
of investing in our securities discussed under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and under similar headings in the other documents that are incorporated by
reference into this prospectus. You should also carefully read the information incorporated by reference into this prospectus, including our consolidated financial statements, and the exhibits to the registration statement of which this prospectus
is a part. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>References in this prospectus to &#147;Arcus&#148;, &#147;the Company,&#148; &#147;we&#148;, &#147;us&#148; and
&#147;our&#148; refer to Arcus Biosciences,&nbsp;Inc., a Delaware corporation, and its consolidated subsidiaries, if any, unless otherwise specified. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Arcus Biosciences, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on creating
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> cancer therapies. Our initial focus has been on well-characterized biological pathways with significant scientific data supporting their importance. We
have built a robust and highly efficient drug discovery capability designed to create highly differentiated small molecules, which we have the ability to develop in combinations with our monoclonal antibodies through rationally designed,
indication-specific, adaptive clinical trial designs. Our vision is to create, develop and commercialize highly differentiated combination cancer therapies that have the potential to cure. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Associated with our Business </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
business is subject to numerous risks. You should read these risks before you invest in our common stock. In particular, our risks include, but are not limited to, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The impact of the COVID-19 pandemic and related risks could have a material adverse impact on our research and
development programs and financial condition; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are early in our development efforts. If we are unable to develop, obtain regulatory approval for and
commercialize our investigational products, or experience significant delays in doing so, our business will be materially harmed; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical drug development is&nbsp;a lengthy, expensive and uncertain process. The results of preclinical studies
and early clinical trials are not always predictive of future results. Any&nbsp;investigational product&nbsp;that we advance into clinical trials may not achieve favorable results in later clinical trials, if any, or receive marketing approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Enrollment and retention of subjects in clinical trials is expensive and time consuming, can be made more
difficult or rendered impossible by competing treatments, clinical trials of competing investigational products, and COVID-19 and other public health epidemics, each of which could result in significant delays and additional costs in our product
development activities, or in the failure of such activities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we do not achieve our product development goals in the time frames we announce and expect, the
commercialization of our investigational products may be delayed, our share price may decline and our commercial prospects may be adversely affected; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Preliminary and interim data from our clinical studies that we announce or publish from time to time are subject
to audit and verification procedures that could result in material changes in the final data and may change as more patient data become available; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Serious adverse events, undesirable side effects or other unexpected properties of our investigational products
may be identified during development or after approval, which could lead to the discontinuation of our clinical development programs, refusal by regulatory authorities to approve our investigational products or limitations on the use of our
investigational products or, if discovered following marketing approval, revocation of marketing authorizations or subsequent limitations on the use of our investigational products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our clinical trials and perform some of our research and preclinical studies.
If these third parties do not satisfactorily carry out their contractual duties or fail to meet expected deadlines, our development programs may be delayed or subject to increased costs, each of which may have an adverse effect on our business and
prospects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are currently party to several <FONT STYLE="white-space:nowrap">in-license</FONT> agreements under which we
acquired rights to use, develop, manufacture and/or commercialize certain of our investigational products. If we breach our obligations under these agreements, we may be required to pay damages, lose our rights to these investigational products or
both, which would adversely affect our business and prospects; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We expect to depend on collaboration with Gilead for the research, development, manufacture and commercialization
of our investigational products. If this collaboration is not successful, our business could be adversely affected. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate
Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We were incorporated in Delaware on April&nbsp;30, 2015. Our principal executive offices are located at 3928 Point Eden
Way, Hayward, CA 94545, and our telephone <FONT STYLE="white-space:nowrap">number&nbsp;is&nbsp;(510)&nbsp;694-6200.&nbsp;Our&nbsp;website</FONT> address is www.arcusbio.com. The information on, or that can be accessed through, our website is not
part of this prospectus. We have included our website address as an inactive textual reference only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Arcus Biosciences and the Arcus
Biosciences logo are the property of Arcus. Trade names, trademarks and service marks of other companies appearing in this prospectus are the property of their respective holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>The Securities We May Offer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may offer
shares of our common stock and preferred stock, various series of debt securities and/or warrants to purchase any of such securities, either individually or in combination, from time to time under this prospectus, together with the applicable
prospectus supplement and any related free writing prospectus, at prices and on terms to be determined by market conditions at the time of any offering. There is no limit on the aggregate amount of the securities that we may offer pursuant to the
registration statement of which this prospectus is a part. We may also offer common stock, preferred stock and/or debt securities upon the exercise of warrants. This prospectus provides you with a general description of the securities we may offer.
Each time we offer a type or series of securities under this prospectus, we will provide a prospectus supplement that will describe the specific amounts, prices and other important terms of the securities, including, to the extent applicable: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">designation or classification; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">aggregate principal amount or aggregate offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maturity date, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">original issue discount, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">rates and times of payment of interest or dividends, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">redemption, conversion, exercise, exchange or sinking fund terms, if any; </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments
in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ranking; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictive covenants, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting or other rights, if any; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">material or special U.S. federal income tax considerations, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement and any related free writing prospectus that we may authorize to be provided to you may also add, update
or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement or free writing prospectus will offer a security that is not registered and described in this
prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>THIS PROSPECTUS MAY&nbsp;NOT BE USED TO
CONSUMMATE A SALE OF SECURITIES UNLESS IT IS ACCOMPANIED BY A PROSPECTUS SUPPLEMENT. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities directly to investors
or to or through agents, underwriters or dealers. We and our agents or underwriters, reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities to or through agents or underwriters, we will
include in the applicable prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the names of those agents or
underwriters; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; applicable fees, discounts and
commissions to be paid to them; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; details regarding over-allotment
options, if any; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the net proceeds to us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Common Stock</I>. We may issue shares of our common stock from time to time. The holders of our common stock are
entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. Subject to preferences that may be applicable to any outstanding shares of preferred stock, the holders of common stock are entitled to receive
ratably such dividends as may be declared by our board of directors out of legally available funds. Upon our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in all assets remaining after payment of
liabilities and the liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights and no right to convert their common stock into any other securities. There are no redemption or sinking fund
provisions applicable to our common stock. In this prospectus, we have summarized certain general features of the common stock under &#147;Description of Capital Stock &#151; Common Stock.&#148;&nbsp;We urge you, however, to read the applicable
prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to any common stock being offered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Preferred Stock.</I> We may issue shares of our preferred stock from time to time, in one or more series. Our board of directors will
determine the designations, voting powers, preferences and rights of the preferred stock, as well as the qualifications, limitations or restrictions thereof, including dividend rights, conversion rights, preemptive rights, terms of redemption or
repurchase, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of any series. Convertible preferred stock will be convertible into our common stock or exchangeable for other securities.
Conversion may be mandatory or at your option and would be at prescribed conversion rates. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we sell any series of preferred stock under this prospectus, we will fix the
designations, voting powers, preferences and rights of the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series.
We will file as an exhibit to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that contains the terms of the series of
preferred stock we are offering. In this prospectus, we have summarized certain general features of the preferred stock under &#147;Description of Capital Stock &#151; Preferred Stock.&#148; We urge you, however, to read the applicable prospectus
supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the series of preferred stock being offered, as well as the complete certificate of designation that contains the terms of the applicable
series of preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Debt Securities.</I> We may issue debt securities from time to time, in one or more series, as either
senior or subordinated debt or as senior or subordinated convertible debt. The senior debt securities will rank equally with any other unsecured and unsubordinated debt. The subordinated debt securities will be subordinate and junior in right of
payment, to the extent and in the manner described in the instrument governing the debt, to all of our senior indebtedness. Convertible debt securities will be convertible into or exchangeable for our common stock or other securities. Conversion may
be mandatory or at your option and would be at prescribed conversion rates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any debt securities issued under this prospectus will be
issued under one or more documents called indentures, which are contracts between us and a national banking association or other eligible party, as trustee. In this prospectus, we have summarized certain general features of the debt securities under
&#147;Description of Debt Securities.&#148; We urge you, however, to read the applicable prospectus supplement (and any free writing prospectus that we may authorize to be provided to you) related to the series of debt securities being offered, as
well as the complete indentures that contain the terms of the debt securities. We have filed the form of indenture as an exhibit to the registration statement of which this prospectus is a part, and supplemental indentures and forms of debt
securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Warrants.</I> We may issue warrants for the purchase of common stock, preferred stock and/or debt securities in one or more series. We may
issue warrants independently or in combination with common stock, preferred stock and/or debt securities. In this prospectus, we have summarized certain general features of the warrants under &#147;Description of Warrants.&#148; We urge you,
however, to read the applicable prospectus supplement (and any related free writing prospectus that we may authorize to be provided to you) related to the particular series of warrants being offered, as well as any warrant agreements and warrant
certificates that contain the terms of the warrants. We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as exhibits to the registration statement of which this
prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form of warrant and/or the warrant agreement and warrant
certificate, as applicable, that contain the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any warrants issued under this prospectus may be evidenced by warrant certificates. Warrants also may be issued under an applicable warrant
agreement that we enter into with a warrant agent. We will indicate the name and address of the warrant agent, if applicable, in the prospectus supplement relating to the particular series of warrants being offered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Proceeds </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in
any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with a specific offering, we currently intend to use the net proceeds from the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sale of the securities offered by us hereunder, if any, for working capital, capital expenditures and other general corporate purposes. See &#147;Use of Proceeds&#148; in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New York Stock Exchange Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on the New York Stock Exchange under the symbol &#147;RCUS.&#148; The applicable prospectus supplement will contain information, where applicable, as to other listings, if any, on the New York Stock Exchange or other
securities exchange of the securities covered by the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We qualify as an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company
may take advantage of relief from certain reporting requirements and other burdens that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced obligations with respect to financial data, including presenting only two years of audited financial
statements in addition to any required unaudited interim financial statements and only two years of selected financial data; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exemption from compliance with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes Oxley
Act of 2002, or the Sarbanes Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight
Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduced disclosure obligations about our executive compensation arrangements in our periodic reports, proxy
statements and registration statements; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exemptions from the requirements
<FONT STYLE="white-space:nowrap">of&nbsp;holding&nbsp;non-binding&nbsp;advisory&nbsp;votes</FONT> on executive compensation or golden parachute arrangements. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may take advantage of these provisions until December&nbsp;31, 2023, or such earlier time that we no longer qualify as an emerging growth company. We may
choose to take advantage of some but not all of these reduced reporting burdens. We would cease to be an emerging growth company if we have more than $1.07&nbsp;billion in annual gross revenue, have more than $700&nbsp;million in market value of our
capital stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> or issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible&nbsp;debt&nbsp;over</FONT> a three-year period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to
private companies. We have elected to avail ourselves of the extended transition period for complying with new or revised financial accounting standards. As a result of the accounting standards election, we will not be subject to the same
implementation timing for new or revised accounting standards as other public companies that are not emerging growth companies which may make comparison of our financials to those of other public companies more difficult. Additionally, because we
have taken advantage of certain reduced reporting requirements, the information contained herein may be different from the information you receive from other public companies in which you hold stock. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully
the risks and uncertainties described under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement and any related free writing prospectus, and discussed under the section entitled &#147;Risk Factors&#148; contained
in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments thereto reflected in subsequent filings
with the SEC, which are incorporated by reference into this prospectus in their entirety, together with other information in this prospectus, the documents incorporated by reference and any free writing prospectus that we may authorize for use in
connection with a specific offering. The risks described in these documents are not the only ones we face, but those that we consider to be material. There may be other unknown or unpredictable economic, business, competitive, regulatory or other
factors that could have material adverse effects on our future results. Past financial performance may not be a reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If
any of these risks actually occurs, our business, financial condition, results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your
investment. Please also read carefully the section below entitled &#147;Special Note Regarding Forward-Looking Statements.&#148;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_4"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and the documents we have filed with the SEC that are incorporated by reference contain &#147;forward-looking statements&#148;
within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, or the Exchange Act. These statements relate to future events or to our future
operating or financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements
expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our relationship with Gilead; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the uses of the net proceeds from the sale of our securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the timing and achievement of our investigational product development activities and
ongoing and planned clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations for reporting data from clinical trials in certain timeframes; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop intra-portfolio combinations and highly-differentiated small-molecule investigational
products, including our ability to create small-molecule investigational products with ideal pharmacological properties and desired clinical effects; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the efficiency and speed with which we can create and advance small-molecule
investigational products and develop our investigational products and combination therapies; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our ongoing and future clinical trials and third-party manufacturers to
manufacture and supply our investigational products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the nature of the immuno-oncology pathways we are targeting, the size of the potential
patient population and the potential market size; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain control of our combination investigational products and maximize the
commercial potential of our investigational products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain regulatory approvals of our investigational products, the potential market
opportunities for commercializing our investigational products; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to retain and recruit key personnel, estimates of our expenses, future revenue, capital requirements
and our needs for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop, acquire and advance investigational products into, and successfully complete, clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our initiation, timing, progress and results of future research and development programs, preclinical studies and
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain and maintain intellectual property rights covering our investigational products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the developments and projections relating to our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations as to the effect that the COVID-19 pandemic will have on our company; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding future developments in our industry. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148;
&#147;could,&#148; &#147;would,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;projects,&#148; &#147;predicts,&#148; &#147;potential&#148; and similar expressions intended to
identify forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and are subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on
these forward-looking statements. We discuss in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
greater detail many of these risks under the heading &#147;Risk Factors&#148; contained in the applicable prospectus supplement, in any free writing prospectuses we may authorize for use in
connection with a specific offering, and in our most recent annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and in our most recent quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as any amendments
thereto reflected in subsequent filings with the SEC, which are incorporated by reference into this prospectus in their entirety. Also, these forward-looking statements represent our estimates and assumptions only as of the date of the document
containing the applicable statement. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Thus, you should not assume that our silence over
time means that actual events are bearing out as expressed or implied in such forward-looking statements. You should read this prospectus, any applicable prospectus supplement, together with the documents we have filed with the SEC that are
incorporated by reference and any free writing prospectus that we may authorize for use in connection with a specific offering completely and with the understanding that our actual future results may be materially different from what we expect. We
qualify all of the forward-looking statements in the foregoing documents by these cautionary statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in any applicable prospectus supplement or in any free writing prospectuses we have authorized for use in connection with
a specific offering, we currently intend to use the net proceeds from the sale of the securities offered by us hereunder, if any, for working capital, capital expenditures and other general corporate purposes, which may include costs of funding
future acquisitions or for any other purpose we describe in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 400,000,000 shares of common stock, $0.0001 par value per share, and 10,000,000 shares of preferred
stock, $0.0001 par value per share. A description of material terms and provisions of our certificate of incorporation and bylaws affecting the rights of holders of our capital stock is set forth below. The description is intended as a summary, and
is qualified in its entirety by reference to our certificate of incorporation and the bylaws. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividend Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to preferences
that may apply to shares of preferred stock outstanding at the time, the holders of outstanding shares of our common stock are entitled to receive dividends out of funds legally available if our board of directors, in its discretion, determines to
issue dividends and only then at the times and in the amounts that our board of directors may determine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our common stock are entitled to one vote per share. Stockholders do not have the ability to cumulate votes for the election of
directors. Our amended and restated certificate of incorporation and amended and restated bylaws provide for a classified board of directors consisting of three classes of approximately equal size, each serving staggered three-year terms. Only one
class of directors will be elected at each annual meeting of our stockholders, with the other classes continuing for the remainder of their respective three-year terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Preemptive or Similar Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our
common stock is not entitled to preemptive rights and is not subject to conversion, redemption or sinking fund provisions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Right to Receive
Liquidation Distributions </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon our dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> the assets legally
available for distribution to our stockholders are distributable ratably among the holders of our common stock, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights and payment of liquidation preferences,
if any, on any outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, subject to limitations prescribed by Delaware law, to issue up to 10,000,000 shares of preferred stock in
one or more series, to establish from time to time the number of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any associated qualifications, limitations or
restrictions. Our board of directors also can increase or decrease the number of shares of any series, but not below the number of shares of that series then outstanding, without any further vote or action by our stockholders. Our board of directors
may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in
connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in control of our company and may adversely affect the market price of our common stock and
the voting and other rights of the holders of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will fix the designations, voting powers, preferences and rights of
the preferred stock of each series we issue under this prospectus, as well as the qualifications, limitations or restrictions thereof, in the certificate of designation relating to that series. We will file as an exhibit to the registration
statement of which this prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
is a part, or will incorporate by reference from reports that we file with the SEC, the form of any certificate of designation that contains the terms of the series of preferred stock we are
offering. We will describe in the applicable prospectus supplement the terms of the series of preferred stock being offered, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares we are offering; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the liquidation preference per share; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate, period and payment date and method of calculation for dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends will be cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if
cumulative, the date from which dividends will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those
redemption and repurchase rights; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange or market; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price,
or how it will be calculated, and the conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the preferred stock will be exchangeable into debt securities, and, if applicable, the exchange price, or
how it will be calculated, and the exchange period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">preemptive rights, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">restrictions on transfer, sale or other assignment; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interests in the preferred stock will be represented by depositary shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of material United States federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate,
dissolve or wind up our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with
the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Provisions of our Certificate of Incorporation and Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Law </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are governed by the provisions of
Section&nbsp;203 of the Delaware General Corporation Law regulating corporate takeovers. This section prevents some Delaware corporations from engaging, under some circumstances, in a business combination, which includes a merger or sale of at least
10% of the corporation&#146;s assets with any interested stockholder, meaning a stockholder who, together with affiliates and associates, owns or, within three years prior to the determination of interested stockholder status, did own 15% or more of
the corporation&#146;s outstanding voting stock, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the transaction is approved by the board of directors prior to the time that the interested stockholder became an
interested stockholder; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">upon closing of the transaction that resulted in the stockholder becoming an interested stockholder, the
interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction began, excluding for purposes of determining the voting stock outstanding those shares owned (i)&nbsp;by persons who are
directors and also officers and (ii)&nbsp;employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subsequent to such time that the stockholder became an interested stockholder the business combination is
approved by the board of directors and authorized at an annual or special meeting of stockholders by at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A Delaware corporation may&nbsp;&#147;opt out&#148;&nbsp;of these provisions with an express provision in its original
certificate of incorporation or an express provision in its certificate of incorporation or amended and restated bylaws resulting from a stockholders&#146;&nbsp;amendment approved by at least a majority of the outstanding voting shares. We have not
opted out of these provisions. As a result, mergers or other takeover or change in control attempts of us may be discouraged or prevented. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Certificate of Incorporation and Bylaw Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws include a number of provisions that may have the effect of deterring
hostile takeovers or delaying or preventing changes in control of our management team, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Board of Directors Vacancies.</I>&nbsp;Our amended and restated certificate of incorporation and amended and
restated bylaws authorize our board of directors to fill vacant directorships, including newly-created seats. In addition, the number of directors constituting our board of directors may be set only by resolution adopted by a majority vote of our
entire board of directors. These provisions prevent a stockholder from increasing the size of our board of directors and gaining control of our board of directors by filling the resulting vacancies with its own nominees.; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Classified Board.</I>&nbsp;Our amended and restated certificate of incorporation and amended and restated
bylaws provide that our board of directors is classified into three classes of directors, each of which hold office for a three-year term. In addition, directors may only be removed from the board of directors for cause and only by the approval of
66 2/3% of our then-outstanding shares of our common stock. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority
of the directors on a classified board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Stockholder Action; Special Meeting of Stockholders.</I>&nbsp;Our amended and restated certificate of
incorporation provide that stockholders are not able to take action by written consent, and are only able to take action at annual or special meetings of our stockholders. Stockholders are not be permitted to cumulate their votes for the election of
directors. Our amended and restated bylaws further provide that special meetings of our stockholders may be called only by a majority vote of our entire board of directors, the chairman of our board of directors or our chief executive officer;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Advance Notice Requirements for Stockholder Proposals and Director Nominations.</I>&nbsp;Our amended and
restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at any meeting of stockholders. Our amended and restated
bylaws also specify certain requirements regarding the form and content of a stockholder&#146;s notice. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for
directors at our meetings of stockholders; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Issuance of Undesignated Preferred Stock.</I>&nbsp;Our board of directors have the authority, without further
action by the holders of common stock, to issue up to 10,000,000 shares of undesignated preferred </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
stock with rights and preferences, including voting rights, designated from time to time by the board of directors. The existence of authorized but unissued shares of preferred stock enable our
board of directors to render more difficult or discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a
claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws or any action asserting a claim against us that is governed by the internal affairs
doctrine. The enforceability of similar choice of forum provisions in other companies&#146;&nbsp;certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions in our
certificate of incorporation to be inapplicable or unenforceable.&nbsp;This provision does not apply to actions arising under the Securities Act or the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is Computershare Trust Company, N.A. The transfer agent&#146;s address is&nbsp;250 Royall Street, Canton, Massachusetts 02021, and its telephone number is
<FONT STYLE="white-space:nowrap">(800)&nbsp;962-4284.</FONT> The transfer agent for any series of preferred stock that we may offer under this prospectus will be named and described in the prospectus supplement related to that series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on
the New York Stock Exchange under the symbol &#147;RCUS.&#148; The applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the New&nbsp;York Stock Exchange or any securities market or other
exchange of the preferred stock covered by such prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time, in one or more series, as either senior or subordinated debt or as senior or subordinated
convertible debt. While the terms we have summarized below will apply generally to any debt securities that we may offer under this prospectus, we will describe the particular terms of any debt securities that we may offer in more detail in the
applicable prospectus supplement. The terms of any debt securities offered under a prospectus supplement may differ from the terms described below. Unless the context requires otherwise, whenever we refer to the indenture, we also are referring to
any supplemental indentures that specify the terms of a particular series of debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the debt securities under the
indenture that we will enter into with the trustee named in the indenture. The indenture will be qualified under the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act. We have filed the form of indenture as an exhibit to the
registration statement of which this prospectus is a part, and supplemental indentures and forms of debt securities containing the terms of the debt securities being offered will be filed as exhibits to the registration statement of which this
prospectus is a part or will be incorporated by reference from reports that we file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following summary of material
provisions of the debt securities and the indenture is subject to, and qualified in its entirety by reference to, all of the provisions of the indenture applicable to a particular series of debt securities. We urge you to read the applicable
prospectus supplements and any related free writing prospectuses related to the debt securities that we may offer under this prospectus, as well as the complete indenture that contains the terms of the debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture does not limit the
amount of debt securities that we may issue. It provides that we may issue debt securities up to the principal amount that we may authorize and may be in any currency or currency unit that we may designate. Except for the limitations on
consolidation, merger and sale of all or substantially all of our assets contained in the indenture, the terms of the indenture do not contain any covenants or other provisions designed to give holders of any debt securities protection against
changes in our operations, financial condition or transactions involving us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the debt securities issued under the indenture
as &#147;discount securities,&#148; which means they may be sold at a discount below their stated principal amount. These debt securities, as well as other debt securities that are not issued at a discount, may be issued with &#147;original issue
discount,&#148; or OID, for U.S. federal income tax purposes because of interest payment and other characteristics or terms of the debt securities. Material U.S. federal income tax considerations applicable to debt securities issued with OID will be
described in more detail in any applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of
the series of debt securities being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit upon the aggregate principal amount that may be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the maturity date or dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the form of the debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the applicability of any guarantees; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities rank as senior debt, senior subordinated debt, subordinated debt or any combination
thereof, and the terms of any subordination; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the price (expressed as a percentage of the aggregate principal amount thereof) at which such debt securities
will be issued is a price other than the principal amount thereof, the portion of the principal amount thereof payable upon declaration of acceleration of the maturity thereof, or if applicable, the portion of the principal amount of such debt
securities that is convertible into another security or the method by which any such portion shall be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the interest rate or rates, which may be fixed or variable, or the method for determining the rate and the date
interest will begin to accrue, the dates interest will be payable and the regular record dates for interest payment dates or the method for determining such dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our right, if any, to defer payment of interest and the maximum length of any such deferral period;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the date or dates after which, or the period or periods during which, and the price or prices at
which, we may, at our option, redeem the series of debt securities pursuant to any optional or provisional redemption provisions and the terms of those redemption provisions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates, if any, on which, and the price or prices at which we are obligated, pursuant to any mandatory
sinking fund or analogous fund provisions or otherwise, to redeem, or at the holder&#146;s option to purchase, the series of debt securities and the currency or currency unit in which the debt securities are payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which we will issue the series of debt securities, if other than denominations of $1,000 and
any integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any and all terms, if applicable, relating to any auction or remarketing of the debt securities of that series
and any security for our obligations with respect to such debt securities and any other terms which may be advisable in connection with the marketing of debt securities of that series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities of the series shall be issued in whole or in part in the form of a global security or
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which such global security or securities may be exchanged in whole or in
part for other individual securities, and the depositary for such global security or securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the provisions relating to conversion or exchange of any debt securities of the series and the
terms and conditions upon which such debt securities will be so convertible or exchangeable, including the conversion or exchange price, as applicable, or how it will be calculated and may be adjusted, any mandatory or optional (at our option or the
holders&#146; option) conversion or exchange features, the applicable conversion or exchange period and the manner of settlement for any conversion or exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if other than the full principal amount thereof, the portion of the principal amount of debt securities of the
series which shall be payable upon declaration of acceleration of the maturity thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the covenants applicable to the particular debt securities being issued, including,
among others, the consolidation, merger or sale covenant; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the events of default with respect to the securities and any change in the right of
the trustee or the holders to declare the principal, premium, if any, and interest, if any, with respect to such securities to be due and payable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in or deletions of the provisions relating to covenant defeasance and legal defeasance;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to satisfaction and discharge of the indenture;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">additions to or changes in the provisions relating to the modification of the indenture both with and without the
consent of holders of debt securities issued under the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of payment of debt securities if other than U.S. dollars and the manner of determining the
equivalent amount in U.S. dollars; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether interest will be payable in cash or additional debt securities at our or the holders&#146; option and the
terms and conditions upon which the election may be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if any, upon which we will pay amounts in addition to the stated interest, premium, if
any and principal amounts of the debt securities of the series to any holder that is not a &#147;United States person&#148; for federal tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any restrictions on transfer, sale or assignment of the debt securities of the series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities, any
other additions or changes in the provisions of the indenture, and any terms that may be required by us or advisable under applicable laws or regulations. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion or Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
set forth in the applicable prospectus supplement the terms on which a series of debt securities may be convertible into or exchangeable for our common stock or our other securities. We will include provisions as to settlement upon conversion or
exchange and whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of shares of our common stock or our other securities that the holders of the series of
debt securities receive would be subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger or Sale </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the indenture will not contain
any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of our assets as an entirety or substantially as an entirety. However, any successor to or acquirer of such assets (other than a
subsidiary of ours) must assume all of our obligations under the indenture or the debt securities, as appropriate. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default under the
Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the prospectus supplement applicable to a particular series of debt securities, the following
are events of default under the indenture with respect to any series of debt securities that we may issue: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay any installment of interest on any series of debt securities, as and when the same shall become
due and payable, and such default continues for a period of 90 days; provided, however, that a valid extension of an interest payment period by us in accordance with the terms of any indenture supplemental thereto shall not constitute a default in
the payment of interest for this purpose; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to pay the principal of, or premium, if any, on any series of debt securities as and when the same
shall become due and payable whether at maturity, upon redemption, by declaration or otherwise, or in any payment required by any sinking or analogous fund established with respect to such series; provided, however, that a valid extension of the
maturity of such debt securities in accordance with the terms of any indenture supplemental thereto shall not constitute a default in the payment of principal or premium, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we fail to observe or perform any other covenant or agreement contained in the debt securities or the
indenture, other than a covenant specifically relating to another series of debt securities, and our failure continues for 90&nbsp;days after we receive written notice of such failure, requiring the same to be remedied and stating that such is a
notice of default thereunder, from the trustee or holders of at least 25% in aggregate principal amount of the outstanding debt securities of the applicable series; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if specified events of bankruptcy, insolvency or reorganization occur. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If an event of default with respect to debt securities of any series occurs and is
continuing, other than an event of default specified in the last bullet point above, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series, by notice to us in writing, and to the
trustee if notice is given by such holders, may declare the unpaid principal of, premium, if any, and accrued interest, if any, due and payable immediately. If an event of default specified in the last bullet point above occurs with respect to us,
the principal amount of and accrued interest, if any, of each issue of debt securities then outstanding shall be due and payable without any notice or other action on the part of the trustee or any holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of a majority in principal amount of the outstanding debt securities of an affected series may waive any default or event of
default with respect to the series and its consequences, except defaults or events of default regarding payment of principal, premium, if any, or interest, unless we have cured the default or event of default in accordance with the indenture. Any
waiver shall cure the default or event of default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture, if an event of default under an indenture shall
occur and be continuing, the trustee will be under no obligation to exercise any of its rights or powers under such indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have
offered the trustee reasonable indemnity. The holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available
to the trustee, or exercising any trust or power conferred on the trustee, with respect to the debt securities of that series, provided that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the direction so given by the holder is not in conflict with any law or the applicable indenture; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">subject to its duties under the Trust Indenture Act, the trustee need not take any action that might involve it
in personal liability or might be unduly prejudicial to the holders not involved in the proceeding. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of the
debt securities of any series will have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies only if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holder has given written notice to the trustee of a continuing event of default with respect to that series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of at least 25% in aggregate principal amount of the outstanding debt securities of that series have
made written request, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">such holders have offered to the trustee indemnity satisfactory to it against the costs, expenses and liabilities
to be incurred by the trustee in compliance with the request; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate
principal amount of the outstanding debt securities of that series other conflicting directions within 90&nbsp;days after the notice, request and offer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if
any, or interest on, the debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will periodically file statements with the trustee regarding our compliance with specified
covenants in the indenture. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture; Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may change an indenture without the consent of any holders with respect to specific matters: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency in the indenture or in the debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the provisions described above under &#147;Description of Debt Securities&#151;Consolidation,
Merger or Sale;&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated debt securities in addition to or in place of certificated debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to our covenants, restrictions, conditions or provisions such new covenants, restrictions, conditions or
provisions for the benefit of the holders of all or any series of debt securities, to make the occurrence, or the occurrence and the continuance, of a default in any such additional covenants, restrictions, conditions or provisions an event of
default or to surrender any right or power conferred upon us in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add to, delete from or revise the conditions, limitations, and restrictions on the authorized amount, terms,
or purposes of issue, authentication and delivery of debt securities, as set forth in the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the interests of any holder of debt securities of any series in
any material respect; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of the debt securities of any
series as provided above under &#147;Description of Debt Securities&#151;General&#148; to establish the form of any certifications required to be furnished pursuant to the terms of the indenture or any series of debt securities, or to add to the
rights of the holders of any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to evidence and provide for the acceptance of appointment under any indenture by a successor trustee; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with any requirements of the SEC in connection with the qualification of any indenture under the Trust
Indenture Act. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by
us and the trustee with the written consent of the holders of at least a majority in aggregate principal amount of the outstanding debt securities of each series that is affected. However, unless we provide otherwise in the prospectus supplement
applicable to a particular series of debt securities, we and the trustee may make the following changes only with the consent of each holder of any outstanding debt securities affected: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">extending the fixed maturity of any debt securities of any series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or reducing any
premium payable upon the redemption of any series of any debt securities; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reducing the percentage of debt securities, the holders of which are required to consent to any amendment,
supplement, modification or waiver. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Discharge </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except
for specified obligations, including obligations to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">provide for payment; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer or exchange of debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">replace stolen, lost or mutilated debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">pay principal of and premium and interest on any debt securities of the series; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain paying agencies; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">hold monies for payment in trust; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">recover excess money held by the trustee; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">compensate and indemnify the trustee; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">appoint any successor trustee. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to exercise our rights to be discharged, we must deposit with the trustee money or
government obligations sufficient to pay all the principal of, any premium, if any, and interest on, the debt securities of the series on the dates payments are due. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Exchange and Transfer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
issue the debt securities of each series only in fully registered form without coupons and, unless we provide otherwise in the applicable prospectus supplement, in denominations of $1,000 and any integral multiple thereof. The indenture provides
that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company, or DTC, or another depositary named by us and identified in
the applicable prospectus supplement with respect to that series. To the extent the debt securities of a series are issued in global form and as book-entry, a description of terms relating to any book entry securities will be set forth in the
applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the option of the holder, subject to the terms of the indenture and the limitations applicable to
global securities described in the applicable prospectus supplement, the holder of the debt securities of any series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and
aggregate principal amount. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the
applicable prospectus supplement, holders of the debt securities may present the debt securities for exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the
security registrar, at the office of the security registrar or at the office of any transfer agent designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange, we will impose
no service charge for any registration of transfer or exchange, but we may require payment of any taxes or other governmental charges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time designate additional transfer agents or
rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment for the debt securities of each series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we elect to redeem the debt securities of any series, we will not be required to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the
opening of business 15&nbsp;days before the day of mailing of a notice of redemption of any debt securities that may be selected for redemption and ending at the close of business on the day of the mailing; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except
the unredeemed portion of any debt securities we are redeeming in part. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Information Concerning the Trustee </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee, other than during the occurrence and continuance of an event of default under an indenture, undertakes to perform only those
duties as are specifically set forth in the applicable indenture. Upon an event of default under an indenture, the trustee must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject
to this provision, the trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and
liabilities that it might incur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payment and Paying Agents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any
interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are registered at the close of business on the regular record date for the interest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of and any premium and interest on the debt securities of a particular series at the office of the paying agents
designated by us, except that unless we otherwise indicate in the applicable prospectus supplement, we will make interest payments by check that we will mail to the holder or by wire transfer to certain holders. Unless we otherwise indicate in the
applicable prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying
agents that we initially designate for the debt securities of a particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All money we pay to a paying agent or the trustee for the payment of the principal of or any premium or interest on any debt securities that
remains unclaimed at the end of two years after such principal, premium or interest has become due and payable will be repaid to us, and the holder of the debt security thereafter may look only to us for payment thereof. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture and the debt
securities will be governed by and construed in accordance with the internal laws of the State of New York, except to the extent that the Trust Indenture Act of 1939 is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we may include in any applicable prospectus supplements and in any related
free writing prospectuses that we may authorize to be distributed to you, summarizes the material terms and provisions of the warrants that we may offer under this prospectus, which may consist of warrants to purchase common stock, preferred stock
or debt securities and be issued in one or more series. Warrants may be offered independently or in combination with common stock, preferred stock or debt securities offered by any prospectus supplement. While the terms we have summarized below will
apply generally to any warrants that we may offer under this prospectus, we will describe the particular terms of any series of warrants in more detail in the applicable prospectus supplement. The following description of warrants will apply to the
warrants offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of warrants may specify different or additional terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed forms of the warrant agreements and forms of warrant certificates containing the terms of the warrants that may be offered as
exhibits to the registration statement of which this prospectus is a part. We will file as exhibits to the registration statement of which this prospectus is a part, or will incorporate by reference from reports that we file with the SEC, the form
of warrant and/or the warrant agreement and warrant certificate, as applicable, that describe the terms of the particular series of warrants we are offering, and any supplemental agreements, before the issuance of such warrants. The following
summaries of material terms and provisions of the warrants are subject to, and qualified in their entirety by reference to, all the provisions of the form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any
supplemental agreements applicable to a particular series of warrants that we may offer under this prospectus. We urge you to read the applicable prospectus supplement related to the particular series of warrants that we may offer under this
prospectus, as well as any related free writing prospectuses, and the complete form of warrant and/or the warrant agreement and warrant certificate, as applicable, and any supplemental agreements, that contain the terms of the warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the
applicable prospectus supplement the terms of the series of warrants being offered, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the offering price and aggregate number of warrants offered; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency for which the warrants may be purchased; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if applicable, the designation and terms of the securities with which the warrants are issued and the number of
warrants issued with each such security or each principal amount of such security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the principal amount of debt securities purchasable upon
exercise of one warrant and the price at, and currency in which, this principal amount of debt securities may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the number of shares of common stock or
preferred stock, as the case may be, purchasable upon the exercise of one warrant and the price at which these shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of any merger, consolidation, sale or other disposition of our business on the warrant agreements and
the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions for changes to or adjustments in the exercise price or number of securities issuable upon exercise
of the warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which the right to exercise the warrants will commence and expire; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the warrant agreements and warrants may be modified; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations of holding or exercising the
warrants; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of the securities issuable upon exercise of the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights or limitations of or restrictions on the warrants.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before exercising their warrants, holders of warrants will not have any of the rights of holders of the securities
purchasable upon such exercise, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase debt securities, the right to receive payments of principal of, or premium,
if any, or interest on, the debt securities purchasable upon exercise or to enforce covenants in the applicable indenture; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in the case of warrants to purchase common stock or preferred stock, the right to receive dividends, if any, or,
payments upon our liquidation, dissolution or winding up or to exercise voting rights, if any. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will entitle the holder to purchase the securities that we specify in the applicable prospectus supplement at the exercise price
that we describe in the applicable prospectus supplement. The warrants may be exercised as set forth in the prospectus supplement relating to the warrants offered. Unless we otherwise specify in the applicable prospectus supplement, warrants may be
exercised at any time up to the close of business on the expiration date set forth in the prospectus supplement relating to the warrants offered thereby. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of payment and the warrant or warrant certificate, as applicable, properly completed and duly executed at the corporate trust
office of the warrant agent, if any, or any other office, including ours, indicated in the prospectus supplement, we will, as soon as practicable, issue and deliver the securities purchasable upon such exercise. If less than all of the warrants (or
the warrants represented by such warrant certificate) are exercised, a new warrant or a new warrant certificate, as applicable, will be issued for the remaining warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we otherwise
specify in the applicable prospectus supplement, the warrants and any warrant agreements will be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Warrants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant agent, if any, will act solely as our agent under the applicable warrant agreement and will not assume any obligation or
relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the
applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder
of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_9"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We describe global securities in greater detail
below. We refer to those persons who have securities registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons
are the legal holders of the securities. We refer to those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss
below, indirect holders are not legal holders, and investors in securities issued in book-entry form or in street name will be indirect holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue
securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be represented by one or more global securities registered in the name of a financial institution that holds them as depositary
on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of
themselves or their customers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security.
Securities issued in global form will be registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all
payments on the securities to the depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so
under agreements they have made with one another or with their customers; they are not obligated to do so under the terms of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a book-entry security will not own securities directly. Instead, they will own beneficial interests in a global
security, through a bank, broker or other financial institution that participates in the depositary&#146;s book-entry system or holds an interest through a participant. As long as the securities are issued in global form, investors will be indirect
holders, and not holders, of the securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a global security or issue securities in <FONT STYLE="white-space:nowrap">non-global</FONT> form. In these cases, investors
may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of a bank, broker or other financial institution that the investor chooses, and the
investor would hold only a beneficial interest in those securities through an account he or she maintains at that institution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For
securities held in street name, we will recognize only the intermediary banks, brokers and other financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those
securities to them. These institutions pass along the payments they receive to their customers who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors
who hold securities in street name will be indirect holders, not holders, of those securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the
legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in street name or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of
a security or has no choice because we are issuing the securities only in global form. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further
responsibility for the payment or notice even if that holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Similarly, we may want to obtain the
approval of the holders to amend an indenture, to relieve us of the consequences of a default or of our obligation to comply with a particular provision of the indenture or for other purposes. In such an event, we would seek approval only from the
holders, and not the indirect holders, of the securities. Whether and how the holders contact the indirect holders is up to the holders. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special
Considerations For Indirect Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker or other financial institution, either in book-entry
form or in street name, you should check with your own institution to find out: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it handles securities payments and notices; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether it imposes fees or charges; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would handle a request for the holders&#146; consent, if ever required; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if
that is permitted in the future; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">how it would exercise rights under the securities if there were a default or other event triggering the need for
holders to act to protect their interests; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these
matters. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a security that represents one or any other number of individual securities held by a depositary. Generally, all
securities represented by the same global securities will have the same terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each security issued in book-entry form will be
represented by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise
in the applicable prospectus supplement, DTC will be the depositary for all securities issued in book-entry form. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may
not be transferred to or registered in the name of anyone other than the depositary, its nominee or a successor depositary, unless special termination situations arise. We describe those situations below under the section entitled &#147;Special
Situations When a Global Security Will Be Terminated&#148; in this prospectus. As a result of these arrangements, the depositary, or its nominee, will be the sole registered owner and holder of all securities represented by a global security, and
investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker, bank or other financial institution that in turn has an account with the depositary or with
another institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the security, but only an indirect holder of a beneficial interest in the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates that the security will be issued in global form only, then the security will
be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or decide that the securities may no longer be held
through any book-entry clearing system. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations For Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial
institution and of the depositary, as well as general laws relating to securities transfers. We </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor cannot cause the securities to be registered in his or her name, and cannot obtain <FONT
STYLE="white-space:nowrap">non-global</FONT> certificates for his or her interest in the securities, except in the special situations we describe below; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor will be an indirect holder and must look to his or her own bank or broker for payments on the
securities and protection of his or her legal rights relating to the securities, as we describe above; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to sell interests in the securities to some insurance companies and to other
institutions that are required by law to own their securities in <FONT STYLE="white-space:nowrap">non-book-entry</FONT> form; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an investor may not be able to pledge his or her interest in a global security in circumstances where
certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in order for the pledge to be effective; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges
and other matters relating to an investor&#146;s interest in a global security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its
records of ownership interests in a global security, nor do we or any applicable trustee supervise the depositary in any way; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a
global security within its book-entry system use immediately available funds, and your broker or bank may require you to do so as well; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor
holds its interest in a global security, may also have their own policies affecting payments, notices and other matters relating to the securities. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor. We do not monitor and are not responsible for the
actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical certificates
representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests in
securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security will terminate when the following special situations
occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if the depositary notifies us that it is unwilling, unable or no longer qualified to continue as depositary for
that global security and we do not appoint another institution to act as depositary within 90 days; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if we notify any applicable trustee that we wish to terminate that global security; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if an event of default has occurred with regard to securities represented by that global security and has not
been cured or waived. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement may also list additional situations for terminating a global
security that would apply only to the particular series of securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of
the institutions that will be the initial direct holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_10"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, direct sales to the public, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offerings, negotiated transactions, block trades or a combination of these methods. We may sell the securities to or through underwriters or dealers,
through agents, or directly to one or more purchasers. We may distribute securities from time to time in one or more transactions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A prospectus supplement or supplements (and any related free writing prospectus that we may authorize to be provided to you) will describe the
terms of the offering of the securities, including, to the extent applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the name or names of the underwriters, if any; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the purchase price of the securities or other consideration therefor, and the proceeds, if any, we will receive
from the sale; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any over-allotment options under which underwriters may purchase additional securities from us;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any agency fees or underwriting discounts and other items constituting agents&#146; or underwriters&#146;
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any public offering price; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any discounts or concessions allowed or reallowed or paid to dealers; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any securities exchange or market on which the securities may be listed. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time
in one or more transactions at a fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable
underwriting agreement. We may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will be obligated to
purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or concessions allowed or reallowed or paid to dealers may change from time
to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus supplement, naming the underwriter, the nature of any such relationship. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of
securities and we will describe any commissions we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of its appointment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the
public offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the commissions we must
pay for solicitation of these contracts in the prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may provide agents and underwriters with indemnification against civil liabilities,
including liabilities under the Securities Act, or contribution with respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us
in the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All securities we may offer, other than common stock, will be new issues of securities with no
established trading market. Any underwriters may make a market in these securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any
securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriter may engage in over-allotment, stabilizing transactions, short-covering transactions and penalty bids in
accordance with Regulation&nbsp;M under the Exchange Act. Over-allotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the
stabilizing bids do not exceed a specified maximum price. Syndicate-covering or other short-covering transactions involve purchases of the securities, either through exercise of the over-allotment or other option or in the open market after the
distribution is completed, to cover short positions. Penalty bids permit the underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover
short positions. Those activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters or agents that are qualified market makers on the New York Stock Exchange may engage in passive market making transactions in
the common stock on the New York Stock Exchange in accordance with Regulation&nbsp;M under the Exchange Act, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the common stock. Passive market
makers must comply with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest independent bid for such security; if
all independent bids are lowered below the passive market maker&#146;s bid, however, the passive market maker&#146;s bid must then be lowered when certain purchase limits are exceeded. Passive market making may stabilize the market price of the
securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In
compliance with guidelines of the Financial Industry Regulatory Authority, or FINRA, the maximum consideration or discount to be received by any FINRA member or independent broker dealer may not exceed 8% of the aggregate amount of the securities
offered pursuant to this prospectus and any applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_11"></A><A NAME="toc934781_11"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Cooley LLP will pass upon the validity of the securities offered by this prospectus, and any supplement thereto, unless otherwise indicated in
the applicable prospectus supplement. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_12"></A><A NAME="toc934781_12"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual
Report on Form 10-K for the year ended December&nbsp;31, 2019, as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in
reliance on Ernst &amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_13">
</A><A NAME="toc934781_13"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus to any of our
contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this
prospectus for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with
the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at http://www.sec.gov. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc934781_14"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference information from other documents that we file with it, which means that we can disclose
important information to you by referring you to those documents. The information incorporated by reference is considered to be part of this prospectus. Information in this prospectus supersedes information incorporated by reference that we filed
with the SEC prior to the date of this prospectus, while information that we file later with the SEC will automatically update and supersede the information in this prospectus. We incorporate by reference into this prospectus and the registration
statement of which this prospectus is a part the information or documents listed below that we have filed with the SEC (Commission File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38419):</FONT> </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000156459020008972/rcus-10k_20191231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A>, for the year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;5, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Information incorporated by reference into our our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> for the year ended December&nbsp;31, 2019, from our proxy statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000156459020017693/rcus-def14a_20200604.htm">Schedule 14A</A>, filed with
the SEC on April&nbsp;21, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Report on Form <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000156459020021282/rcus-10q_20200331.htm">
<FONT STYLE="white-space:nowrap">10-Q</FONT></A>, for the quarter ended March&nbsp;31, 2020, filed with the SEC on May&nbsp;5, 2020; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000156459020026867/rcus-8k_20200521.htm">May&nbsp;26,
 2020</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000119312520152272/d923203d8k.htm">May&nbsp;27, 2020</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock set forth in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1724521/000119312518077572/d461416d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on March&nbsp;9, 2018, including any amendment or report filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also incorporate by reference any future filings (other than current reports furnished under Item 2.02 or Item 7.01 of Form <FONT
STYLE="white-space:nowrap">8-K</FONT> and exhibits filed on such form that are related to such items unless such Form <FONT STYLE="white-space:nowrap">8-K</FONT> expressly provides to the contrary) made with the SEC pursuant to Sections 13(a),
13(c), 14 or 15(d) of the Exchange Act until we file a post-effective amendment that indicates the termination of the offering of the securities made by this prospectus, which will become a part of this prospectus from the date that such documents
are filed with the SEC. Information in such future filings updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically be deemed to modify and supersede any information in any
document we previously filed with the SEC that is incorporated or deemed to be incorporated herein by reference to the extent that statements in the later-filed document modify or replace such earlier statements. We will furnish without charge to
each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request, a copy of any or all of the documents incorporated by reference into this prospectus but not delivered with the prospectus, including
exhibits that are specifically incorporated by reference into such documents. You should direct any requests for documents to: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Arcus
Biosciences, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attn: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3928 Point Eden Way </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Hayward,&nbsp;CA 94545 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT
STYLE="white-space:nowrap">(510)&nbsp;694-6200</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g918491g32t20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="5"><B>Common stock </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P></center> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>PRELIMINARY PROSPECTUS SUPPLEMENT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="2">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P></center>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Citigroup</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>SVB Leerink</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>Evercore ISI</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; 2020 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:4px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g918491g31a51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g918491g31a51.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2E&4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *2J^$%.#A"24T$!       /QP!6@ #&R5'' (   ( 'QP"4  (<G(R.3
M0Q-C4< @4 'DUI8W)O<V]F="!7;W)D("T@26YS97)T7S0N9&]C>  X0DE-!"
M4      !"46P=I$34"Z;$ P[U]=D#3.$))300Z      #E    $     $
M    MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M   $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<F
MEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
MP 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M  0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#
ML      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M  0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V
M)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M   $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M  4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M           $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M          0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&
M4JI^         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4'
M,     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B
M-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5V
MAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
MQC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M     +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      !  J54_  $  @
M"I53\  0 ".$))300F       .             #^    X0DE-! T
M0   !X.$))3009       $    'CA"24T#\P      "0           0 X0D
ME-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M     ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M ! "T    &       !.$))30/X      !P  #_______________________
M______ ^@     _____________________________P/H     /________
M____________________\#Z     #_____________________________ ^
M@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M  .$))300:      ,U    !@             !UP   _@          0
M                     !              /X   !UP
M     !                         !     !        ;G5L;     (
M &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M      3&5F=&QO;F<          $)T;VUL;VYG   !UP    !29VAT;&]N9P
M   _@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@
M    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6
M=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'
MEP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M        !"=&]M;&]N9P   =<     4F=H=&QO;F<   /X     W5R;%1%6%
M0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&
M-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94
MAO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6
M-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $4
M53;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M     *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M      "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M      .$))3001       ! 0 X0DE-!!0       0    $.$))300,     !
M[+     0   *    !*   !X   BL   !ZO !@  ?_8_^(,6$E#0U]04D]&24
MQ%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$
MU31E0     245#('-21T(               $  /;6  $     TRU(4" @
M
M 18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=    @
M0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN9
M   E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'
M5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M@,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&
M,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G
M-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C
M$
M       %A96B        #S40 !     1;,6%E:(
M!865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(
M       "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96
M,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                  9&5S8P
M     N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2
M!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;V
MQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M      +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-B
MTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6
MX@245#-C$Y-C8M,BXQ                                  !V:65W
M     3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4
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M$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q GH"A
M*. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#9@-R W
MX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@
M2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?
M8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'=
M>&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3
MH)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@
MLY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5
MH-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP
M_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F
M02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!
M56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&
M48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LA
MO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'V
MD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."
M-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))W
MHGJR?<* TH/RAQ**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2
MP%+#DL;BRB+-<M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*
M0PVS$2,4HQ@C&Z,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS
M7"-?TV-S9R-JXVZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N
M\[+3MK.ZH[Z#PG/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$
M"F0.=!*4%J0:Q![D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F
M=&JT;P1S5'>T? 2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<D
MRZ30)-2DV33=Q.)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q
M-37U.J4_940E2/5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%
MH'6E9:IEKU6T5;E5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/
MQA3V&B8?5B26*<8O!C0V.78^MD0&249.EE/6629>=F/6:29NAG/6>39^EH/V
MB6:.QI0VF::?%J2&J?:O=K3VNG:_]L5VRO;0AM8&VY;A)N:V[$;QYO>&_1<"
MMPAG#@<3IQE7'P<DMRIG,!<UUSN'04='!TS'4H=85UX78^=IMV^'=6=[-X$7
MAN>,QY*GF)>>=Z1GJE>P1[8WO"?"%\@7SA?4%]H7X!?F)^PG\C?X1_Y8!'@*
MB!"H%K@<V",(*2@O2#5X.ZA!V$@(3CA4>%JX8.AG*&UX<[AY^(!(AIB,Z),X
MF9B?Z*9(K*BS"+EHO\C&.,RHTQC9B-_XYFCLZ/-H^>D :0;I#6D3^1J)(1DG
MJ2XY--D[:4()2*E/257Y7)EC26GY<*EW67X)A,F+B9))F0F?R::)K5FT*;KY
MP<G(F<]YUDG=*>0)ZNGQV?BY_ZH&F@V*%'H;:B)J*6HP:C=J/FI%:DQZ4XI:
MFF&J:+IOVG;J?@J%*HQ*DWJ:FJ'*J/JP*K=:OIK%RLT*U$K;BN+:ZAKQ:OB[
M  L'6PZK%@L=:R2[+"LSBSKK0EM)RU$[6*M@&V>;;PMVBWX+A9N-&Y2KG"NC
MNZM;LNNZ>\(;R;O16]C[X*OH2^_[]ZO_7 <,#LP6?!X\)?PMO#6,/4Q%'$SL
M5+Q<C&1L;#QT''O\@]R+S).LFYRCC*M\LVR[;,-<RUS37-M<XVSK;/-\^XT#
MG0NM$\T;[2/]+!TT33QM1)U,O53M71UE76V-=<U^#89-CHV6S9\=IVVOO;@-
MP%W(K=$-V6WA
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MTPB?U4JGN)1O"EO_ $?>_K#5=K^YNT6EXLP@Z=..W+=HL_< KD>%CT4&;<2
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MFTULOI4N.HQYH2\A*U(6MI0U@G>H0M"T*6@E*5)4%8((',7<GD@Y!42HUV7
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M5-:D<2TSMO,I+[I;8"G6P7 5IS%N_'G?O--?*&K_ &;ZU[WT-[\%7/TWI_\
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M;7M-NLI4I#80TTEM&)#+XWS+)UB9KZ=(C$'$P,X@+T]\178H-)NU#:%>$)V
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M2W.=B)6L@K6@*2A)[(<75A'#:%>@SM.! 4E +8<VEJ2$@EI+A222!TJQPR<
MD D8/FI::^:JV:P5E26@IX]?F9*&/.5:62G:U,&C7:K0TG 3+;@WEH9\*79,
M9(H "3UFHBY3 "J &M@;7O6FW=AQL.(2L(=06W4;20K9<0<E"TYPI)X@]-62
M,$C@<'&1T'\GQ50> >_\(_IU[I7J9L]'_:A.(AQ +9-E .(_<\:(B(B(\>OK
MX>(/)P   -]TV";?C./O[I'3W$?'\9\N *T+4>3<L X_<[1S@'H*Q^;I/;XU
ME1S@_P"('YOT:V#9/XY_7]-06%?C?Y(IS@_X@?F_1ILG\<_K^FF%?C?Y(IS@
M_P"('YOT:;)_'/Z_IIA7XW^2*S&QQM%L&0-O5ASNE)/V2<3:B1<=!IUUT\:2
ME:C9.J1%KL2L^59-C'*Q+JWM#Q\:Y+TDNA"691-5#M67I]+N.L(]OU'%L!0A
M9?B[UU\RD(<9DO-RW8481B"MP/IA.AQT$!E3L4$*WV42T:T/2+:]< MQ(;="
M4HW)*5LH4TE]TN X26R\C8;P2X$ND'+>%9.S')SX_B[*G$&SE(-F3:S6JG2(
MR,'BY.2?3\$E J1R$(JPS2_K$>>4)+O'98+(-EHMW4904H>.J;]P1)NIJK'*
M3<78JGA8D*<5%AS6PT_=RA$>09 =4^A=B1+=2R64(YS;HL^!O'V]Y,:1E=3"
M]-,)=#?5!P)#CK*]IJ%MEUL(*0WL3U,C:"B=U)?C2<(7LL+("502K[$Z5,HH
M(26:G329C)._,[4T;4EDSBUD:"SLSJ:"DV&X6ZHP\T:!5AX1A;INP.JM1H22
MM48P;6^3<)N"DDIFNY[!6MFS(<8<:MZXBESW%/!5P7$2SS^-"A37V-^E]]R'
M'C(F3Y#<1UQ4)E!23B,6-ES92N>X%I7(0\$QD)01'#Y68[TE^.TX&RVTE]QU
M3,=M3Z$A]:@0+(0VT6V6B_;A*37+'6#$P&:YD=25CFJW3EK&M5K ,(W11BK5
M88=[%H229%G;F7<E5A80Y$6<H^1<R$>1S-OZPAQ(&G9TF/,'7"(:FVHS$J:(
MR9482%%;T..^VXILE*$-)(>D J<90M#3JD8+=HD.R;BPVZUBW;X+6ZXPQO=T
MYNQLAYU)3M<5$G*4=BE9"EISV,2;>L>Y!Q,YO=BO=OIUB=7R#QQ48MQ2H1S5
M+I;+(_:MF$3"6+NS)/*J0S%P:8N+D*:=C7X_L4J;F1D)!A'N?-VU%<K?>&[?
M'@PYD5-OD7.:\FX/HFP8D9"RMYZ+S%4<)><2&(:3.2Y(=V\H;::==16';V9,
M)4ER2\PZ9*(K"5,-&/(=<4@)0V[S@.E3:5%Q\\W*&VPGLU+6E!GBW)ZY*,5P
M9GDC#1G)72C9I .IJ\)6!59PG>W$"Q5(3'9X5.0L#;'%J.Q*$R+- 6!3R;N.
M0<MUCX(Y0K=MI0JVWK9V0M<A#,$QDH2;>F0Z%&Y!XMQE72&',LAQ>\.X0\4*
MQ>-@E;!6)</).$-$OEU2E)DJ:1A,=2 MY,1[9!6 D@!TM[0K ,1 .'$H#Q#C
MU?\ R_1_G'H !/$*/E)^C]OU00VCVR/B(&?U</)D=O/:&G.#_B!^;]&J[)_'
M/Z_IJN%?C?Y(IS@_X@?F_1ILG\<_K^FF%?C?Y(J$Y+.'L<9!X% !"D6L>/XH
M%^/F#S?_  'Q:Q9P(ARSM'(C/D?EW:L'B2/U5F6X$W" "K(,V(", =,AL=->
M.YC" \ X<.'5[WCZNK@'P &N<@ ]H#9)2,!/0#\8^.NMXV^)Z>WCMY&>.<DG
MC@DDYQFMO/'S!^?].J[(_8)]6FP.Z?U?13GCY@_/^G39'[!/JTV!W3^KZ*<\
M?,'Y_P!.FR/V"?5IL#NG]7T4YX^8/S_ITV1^P3ZM-@=T_J^BG/'S!^?].FR/
MV"?5IL#NG]7T4YX^8/S_ *=-D?L$^K38'=/ZOHISQ\P?G_3ILC]@GU:; [I_
M5]%.>/F#\_Z=-D?L$^K38'=/ZOHISQ\P?G_3ILC]@GU:; [I_5]%.>/F#\_Z
M=-D?L$^K38'=/ZOHISQ\P?G_ $Z;(_8)]6FP.Z?U?13GCY@_/^G39'[!/JTV
M!W3^KZ*<\?,'Y_TZ;(_8)]6FP.Z?U?13GCY@_/\ ITV1^P3ZM-@=T_J^BG/'
MS!^?].FR/V"?5IL#NG]7T4YX^8/S_ITV1^P3ZM-@=T_J^BG/'S!^?].FR/V"
M?5IL#NG]7T4YX^8./D][S_#_ )OQ\:[/]/:';_-^W;S5=@#MGR _SBOI^Y$+
M&6W*R;2MTUOS+AG"F1[D3+V/,<8SG\I8:I67)2 L>0(=.#A$(&-L]=GY!X@V
MF9!*<<5N)2.>8"/6129.G*A$S\GU[/F0[I;"S<)L.(F%(E34QIS\-+C3+@<4
M%+;=;0E3@PPA1&=MQ(&20DR%O;#R5)#:5N*<"4@I2HY5CCT8 2#M+4<)"4E2
MB ":]0(QCM?[3L"FY-W9W-3U>I%>0O;%3:]AIN5/*D>MENOWR#/)0K*46ATG
M%CQ8LI0F"=-DUK(E(IQBR\,\E*\,EKH-U<VB=2WU#3K[G-U=59A)AD0G8SP:
M=<02$M34\X4M]H,%)5LNI2YN[VPCML,DX3M8:01M':VLD= &STX))(&.()SB
MBMH6RV7I\S*L=H>PJQ%1=IDB,A57;GAE"@G8@I  HVD.V$-*.$9D3/Y5(AH]
MU,P@)M&QWDHQ?J.8MKSC6NJM66>RS)5NO]RMTUI$78=O=WEM18Y=N#3+Q><+
MB$(08ZE!E;R&TA]0"]E #AGK#;X$RYQF)D9R3&6I[>,0F J2[LQW5MAM/ K
M=2C;V#ME.UL)40:^)GEB*A1*'R@.8*WC2AU7&M.0K>%GT93J74H&BUV,7F<)
M8]EY15C5ZPV9PD6>2E7SV4>=A(@1V]>.'RBBJKE14_>^2:\3-0\GNF;U/>FO
MR[A"5)>?N"4IEN+6^[V;B=[(V 0$[M*7G$!O8W:BG!J"U!!;M]ZN4)O=;N)+
M=92&%%QK#9QV*U(0I?:!VD!8/8K&T"*^HBIXNV9XVVN;&)MWLYVGW:Q2VW/
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M3=0?/-*_UCIS*-X8MWFKM]EU=.( L RB(R%Y0+%D;%P->F:K%1+6N;J$XAM
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M25.(:24-I<"-3I2M*4%24I4D@!1'')SE-*<98$9K4,)#"5+4E 9N9 4X05D
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MT^_[B/ >(<?^IT=8@/7U^7KUK/N>R_@MY\WI\?\ S$:N<\1^,S\IWV-:C_1
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MLIR$YP"I9'2365/A)<T"F5+V ,>BD4 YJ8XIY4D4PX+%<!P)X+SFAP7(1<.
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M#XPZ]8\Y($*80,?N9_MGMM*'=[E9]M2!<8&!_P .B#I/09#>17CP<>OR>+S
M/E$?-KG*>W\2B!76DC([?:[9']R.X:V<1][X _1KU7K ^/RGZ:<1][X _1I3
M ^/RGZ:<1][X _1I3 ^/RGZ:<1][X _1I3 ^/RGZ:<1][X _1I3 ^/RGZ:<1
M][X _1I3 ^/RGZ:<1][X _1I3 ^/RGZ:<1][X _1I3 ^/RGZ:<1][X _1I3
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MD>7_ '*87W1^WYJ>S]EWV\2O\!&_,M.I\/X,CR_[E,+[H_;\U/9^R[[>)7^
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MF2W%YA)9<=BEL+;EH7*ML:,N.YV.TE#YEL%UL28K!4D&L<E5RJE4WT4TE#R
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MK'0!CIZ1C_NS4-.B2B^=F+)(*$9.Y=P,9X<$<3V1[>.X3C)FPX6S./CQ'DT
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MS4_ZE5Y:-M[PDA!\Q'?9MO=%[-<""S>@;RBIC^P2 2\UUM9;K )?+Q1 .LO
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M/JU.MB=WZ+Y7_84\ #N/](';!\8YQ^Q#3K7F=\A_*<^K4ZV)W?HOE?\ 84\
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M2XOL;86&T:RS@7^)M3(\'<]OBD TQ[8<A9$@&--K\EF',>,X5,L+C:CT>QS
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M.PM\%.04J P 4A' @<9!KE TA(;#K%Y:>:45%+K+$MQM1!*2$J1'4@["@I/
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ME74#&(*A2^R]A'G"0! !,!0N0B)0$0 1 ! !$.(]8<:"RZ?/^&$+'03U)OV
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M'3@Q$4B&4.0H\YY5T;W0UV0%H27'[2@%:TI0DJNT).TLJ( 0$E14H\$A.5$
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M1)\W44:/<\MWC8YVBZ2YD'3=!PB10O3))FXAK75:@U6DD'E!E@I*DJ_?C4!
M4E100%"-@C:20",@D=/:J//)OH1)*5:=T>%))!!LL;.1VN%N(X#Z>@UW>YW
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MV7KOMHE\UXLEXJ!3LN)(2(9-,D0>,*R.*W<N1ODZ[O%^Q%I>"A DIEW0W-<
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MT!K<IB;(*&Y)=2^A:%$592NZ)D+.PXMA3CRTY2PI10HA03Q*CD( #:2>P4%
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MFK-$#3&Z2ALJ9 =0T&L<Z#<)M+KGWM12ZVF.4J=<4 5*S7-W=/%XJ6Y/>*W
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M !CO'RXGU2G,9'A&7\IOV5=9GO9P6U;(H*\G-M,>*)$ AW+AYF4%5A#C_3%
M2R2F3GCQ'G"4H /F#3J+/\8KQ\N*.W_T4_%V_+TES&1X1E_*:]E79[^' _X-
MS:-^69I^TS3J+/\ &.\?+B?5*<QD>$9?RF_94[^' _X-S:-^69I^TS3J+/\
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M?6Z>%IL_N*P/RTD/J_IUKL?"E^91ZU/>[6_QHF^BFOK=4^5Y7.T,8R0>EPC
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MN0YQ3N7B).(EUYVU0T3)<)MRX/NPT../*:CQ2D-,H#CBP5RDE26TG*AC;SG
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MN.K)AZN55U2THDFV7;\]*2<Q1B>W/@7>8\BSJB:9M](GIDZ8\TO1MS/Q;-P
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MW)D-"FKQA<N,@XU3JA)PIY"3A0O&0>/ CB.D<0*QP[[K.'#K?8TX<1X_[0.
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MG./W=C3U [?_ ++M.I$'\63Z0N'UJGN9Z4[S??TSUC]N4[[G./W=C3U [?\
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MO744JY>/GCA11R[=N%#KN7"JBRIC'.(ZEV[G:&D(;;GV]"$)"4(3)CI2E(Z
M %@ "NEPM?\ )G;XK$*)K+1L:+%:;9889OUH;:;;;2$I2VA$D)0D #"0 !T#
MAP#O0]U7HWYQ]5MT^AM>NJUK\(P?G3'KUE^Z7R=^/.DOT@M7UJKVX\VM;E6,
M"=![@',;589!RIT3C'%M14YATT.:?F*1)3<TW 0 W#@(@/ =1DJY6Y3I*9T1
M0V4\4R&2/*%FM+OO*#H5^>%LZQTRZ@,)25MWNW+3M;:SL[29!!(!&0#P[=3K
MO9MQ?N$9<-[WL>VL./O"(18#P\_ 0'S" ]>L;JC ^&Q?/M'_ -ZH<Z[T5@_V
M6:</:_EFW]!X'&7\9QT5?]@YWVQ[MLY#!]D?-XU\S=0,.[P9:F$76VT=19_'
M#!A#NZNK7+69-.J3ZS%1W+6B4D2F;I*,7C$0 H1:F+,H+Q<$I4YM[U8ELDN[
MQT/G:2L*;&RZE) 2A(.R,@\<\ND6/DKD-R?[.(B)$\RC<)1U):WE3#)N+-S)
M>8DJ?BI*9<=E[[PPREPHPZE>2:ICV/WN/V\XW4P-:&P3M5;44ZC/%&6%'455
M$FUI:OF4;*3%IF)M^]ET;G/E=/[=*6KL(R[-:";0SJ,8.4"6;0G=YN*#L.AT
M_NB*$J6DH*<H#80G!0D*W:$%21@E0/"C=CY,&T1TG7MO<#-Q%R4D7;3C++C^
M(0!3%8CMQHQ;-OCD.0T1G'DA3<DNH6X#SF:[U$CV \3MM=5T;#7HZLJD@<,9
M=0:,(R(B)R"B2Q\?(7618%2BXVP28,X!TV=48\@[<3$C4)&676>J4+%H4$[R
MZ;PI>+P4N5%*BHE"E;1W9*E*4A.5\%X  4!T>7+'R:O!OG7*+%EK;G.W#>NW
MK3Q>6](=:>D!;H82LJ<7'CA,G/.V4M[++Z&R6ZMD&'-W@4@<<DQ;G0E-/-,Y
MY>"+2[B5FY>L&SM!JFJF$?P+'%5>K/E8U$$V;F1*W?N45G+1N=//4_:524RC
M)A%Y*%("]ZQD)40<DY!*TD=BK.0,@'B:W1ZZ<F#]\BZA<OVEEW6)',=J2;M:
MMI1*D*2^LEW:4\WNTH8=*MXRV5MI(2H@UQ''6\ D_"3K[".39Q&L0#2M0-6F
M\?Y+=4MM%M*(./3 M M9!B<KZ0A%GRLD_B7T,X7?2#M9 S0JQDM65*M"FWD"
M7%2I]UQU;J7V-Z%+<2[V*E!6$A21A*MH<#D9.:BI Y+GXMY9ZZ-.M2;S/D3W
MKFW=+)U29<D3FYY:8DJ23N&WV_O;3J7 E!"-I1!74@;5_>#&QC"-@MKI:V>&
M?622K,I#84S":2ILA:X2'@9J1K!IN]S; KYPT@V#A)6PQUB1:/TP<M6R)"E1
M"VI-L6HJ<NY<VT(0\%2HF'DMK4M"5A#:",%1SLJ&T."LY-1TJ/H>>\\]<.5%
MJ89D2/;[BA=ZTTVFXPXLMV6RQ)4Q#86AM*WEI)C[IQQ!*'%$#*[=I83W;MZ,
M3&S7%F=6](&8C9Q>O(TZZ$9.7,1&S4:S:K)E8  Q8DGGKQY%D K*0DTH]^^2
M7<1S11+*YQ:2^F29,/?(0I"5[UC@%*2<D9XJ&SA*NE ) X'%;,]=.3!^]1+^
M[?M*KN4.,Y&9?5=K6H[M9:*%+VEE2WXXCH3&>*DN,I<<2A82MQ)DMBH&\JS5
MLE/>8<RG&UOH8!J[90./<AQ*TNRK5#B<=QC"<52<*M95BI Q0*R+-RP,W>2#
ME5=,C5L ,S64*LZ'2^9<5Q>72 X\PI*5.OJ?*D G@H$E .<[.!DU$QT\EC-W
M?N[VI].3GWGKB^AN?=K/(8CO7.X=4WGF$G"FG&9*W$L.!2E(944 !6%FM-:Y
MO21EY&6>X0R%/-7BQ'36EV'&^3GV.HM^VD(F282T?5&DO' UF&3N$CG!9%&2
M34<+)K)N2*,'"S!2VI%F+26Q-CH5D[3Z7V Z4J4LE)*MI)2 L@ IRD@%)VAF
ML)^!R5.041F]6V6-*;<=*;FQ>;)SY;+KLEQ;#RG4N1W6THDN--[4<J0"VX@M
MN-A52--YOV53CR3N'KA<#1\Q,3Z:]EP7-).S2,M7TJX1'MG46E2F&S"-9$54
M8=KY%G,],J"+V=>QB*4<%OFUC&V434-%: @A$UL@X4%$E+F\0HJ([,*!3P[%
M*3A0C^MWDC:WH@ZS@P0[ 8@N!K4MO?;<W$IN4'G69KDEAXN+; 6P\RY'!"'&
MVVGD;ZK%2.WC<]-RLM/3>%LO2$U/2TI.2ST<<V=$KB2F'Z\D^.F@G%B1NAV4
MY5!LW3$Q&[<$T"F,5,!&1:FVYEIME$V+L-(2A/W]KH2, _A#)/221DDDUT&T
M:HT#9K;"M<35FGQ&@1FHS.\O5M*RAM"02LI? *BH*)P ,DD#C4>G]L6X]:#F
M$DL#9?555BWZ:::>.[6<ZBAVJI2$(4(H1,8QA I2@ B81   1$ U?:N-O#K9
M,V( %H))D-  !0/$[7#]LU-PM>Z(;FPW%ZOTVE")<9:U*O5N2E*4/(4I1)D
M   DDFL; VA[JA >&W#.(=8\!]BZZ><?%_68?A_?U,=5K7X1@_.F/7KH1Y2^
M3S! UUI('N]<-J_HE?KKU)VY9#SUA6@J4&X;&,U93C&SQI+5L\GC&Q1[JK2I
M6@HOE(]VXJLPJ*:C@B+MB= &3A@[%VX15$SLP):U<XUOG2!)8OT*(LH+;H1)
M;PXC:40% /)' $ CB#VQT5^9\GD<O)O6II)UIR+7*W734=WO5K$K7K3,F(FX
M3I,M.T#9Y 0Z4N-$AMT;I[>%#A&%&Q=M-O3M]GGK5)8$W%C)3\^[L:PIXTR(
MV1:2#ED>*3,R1:&031[#A3A"MC@3I"QI ;G,<IC@,@P;(PVVTBXVX);;2V,R
M8ZB0"'%9)';<&UV^R&U6FR/N?M927Y$EWE-Y&B[(D*DK Y0'$HWA;W0V0FV\
M AK[VD= 1V(X<##5*IO,.FHW' VXP[95!LT4;*8WR*LV4:L6CE@S;*M7 JMU
MVK9D\=-46S@BJ!&[A9$$^C5.0;V^LOP^W'\+LN=1P1MJVED'9R"HI220.) )
MZ*M(^YVU8 $JY3>1LH 2 A6OUK1LH0IM*2VNV%"DA"U("5#9V21CB:LMD';I
MNUO4\[L<CMZSX_EY60DI67?O<67$JSR0DW97;EP8J<0*9155,J82$ B20"1-
M),J92D+ELW&TLMI;1<8 2@!*4B3' 2D)  R%)S@C)[$9X]LYKZ]^YALMOY(8
M^MDZQY0N3B4_J2=9I45RT:NB3,<Q;N:9)D\Y:A%*EJF-[L)+@P%'@4@&#]Z'
MNJ]&_./JMNGT-JYU6M?A&#\Z8]>OJOW2^3OQYTE^D%J^M4[T/=5Z-^<?5;=/
MH;3JM:_",'YTQZ]/=+Y._'G27Z06KZU3O0]U7HWYQ]5MT^AM.JUK\(P?G3'K
MT]TOD[\>=)?I!:OK5.]#W5>C?G'U6W3Z&TZK6OPC!^=,>O3W2^3OQYTE^D%J
M^M4[T/=5Z-^<?5;=/H;3JM:_",'YTQZ]/=+Y._'G27Z06KZU3O0]U7HWYQ]5
MMT^AM.JUK\(P?G3'KT]TOD[\>=)?I!:OK5.]#W5>C?G'U6W3Z&TZK6OPC!^=
M,>O3W2^3OQYTE^D%J^M4[T/=5Z-^<?5;=/H;3JM:_",'YTQZ]/=+Y._'G27Z
M06KZU3O0]U7HWYQ]5MT^AM.JUK\(P?G3'KT]TOD[\>=)?I!:OK5.]#W5>C?G
M'U6W3Z&TZK6OPC!^=,>O3W2^3OQYTE^D%J^M4[T/=5Z-^<?5;=/H;3JM:_",
M'YTQZ]/=+Y._'G27Z06KZU3O0]U7HWYQ]5MT^AM.JUK\(P?G3'KT]TOD[\>=
M)?I!:OK5.]#W5>C?G'U6W3Z&TZK6OPC!^=,>O3W2^3OQYTE^D%J^M4[T/=5Z
M-^<?5;=/H;3JM:_",'YTQZ]/=+Y._'G27Z06KZU7"AM+W1NDBK-MNN;5T3B<
M"JHXPN2B9A3.9,X%.2'$HB10IB& !XE.4Q1X"40!U6M?A&#\Z8]>GNF<G7CU
MI+](;5]:KF[T/=5Z-^<?5;=/H;3JM:_",'YTQZ]/=+Y._'G27Z06KZU3O0]U
M7HWYQ]5MT^AM.JUK\(P?G3'KT]TOD[\>=)?I!:OK5.]#W5>C?G'U6W3Z&'3J
MM:_",'YTQZ]/=+Y._'K27Z0VKZT:]L\$56+7H^,H#<+B7-[^$HVW=WB-A1F^
M \_NUX^>NDT\=9*F7SN(I)(L7$C",:M"0$E$R;B0B&[::6;/6RTJ8$N>W1J0
MY=.>0+C"0TF8]+*.?6\(>?2(P@/DKD[1$4":0RMO84N2EQ04IELCX7Y1=/\
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M1<3:Z0J/$B0_-3E.E7S4:&V.8VYU+CBFDI?DM*2I" 4C:0TM)*5+4/PEI)"
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MVI54YNR$!X$3)%&.<> "/ I1'@ ]6LF'IS40DLE5AO0&WQ)M,\#H..)9P,G
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MIQEU .TVL#R.0*VJ?YLG7+2I6TI)C)M3)?!0VAU8+2;P5Y0VZTXL8REMUM9
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M9*FHDAN<VMR,!=XJ0Y.W[*WFTA@Q'$-%M<A,9I!MKY.-=.*NRI5Z$PSH<="
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MM,%J(W9&1O)+##KLR07U.2);GWPE)RC;D7/;.^P5MA"5V8;!.$=%B%7=?H;
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M,N6DJDIV]6Q!/=>2K>;@LR4J<?1S=&&YR6:O1<GKA!O28KKDU,U"VKO>CNI
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M<,VLKFRM%0CY)!_;UIY"LLFK\CMM$H3"HA-/OU?NW*YR?3+/,98U1IS?W!J
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(I2FE*:4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g918491g32t20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g918491g32t20.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X6#Z:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^4')I;G0\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.
M86UE.B @(" @(" @(" @(" @('!G,C<N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(R.34U-C0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(#(X+5-E<"TR,#$Y(#$P.C0T.C4V)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(#(X+5-E<"TR,#$Y(# Q.C$T.C4V)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.^* HB Q-"!#35E+(&)L86-K(&]B:F5C=',@8VAA;F=E9"!T;R!G<F%Y<V-A
M;&4N)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @(" @(#PO
M<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @(" @/"]R
M9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z365T861A=&%$871E/C(P,3DM,#DM,CA4,3 Z-#4Z,C@K,#4Z,S \+WAM
M<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#$Y
M+3 Y+3(X5#$P.C0U.C(X*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @
M(" @/'AM<#I#<F5A=&5$871E/C(P,3DM,#DM,CA4,3 Z-#4Z,3<K,#4Z,S \
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D
M;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A=&]R5&]O
M;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C@T/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @
M/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @
M(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%
M05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!
M04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&:V(R2FQ!1U1!
M04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#
M=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(
M>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&8O.$%!15%G059!14%!=T52)B-X03M!04E205%-4D%F
M+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%
M04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!
M0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC6455
M37!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#
M3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT
M+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD
M-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ
M8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!
M341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C13
M3D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG
M6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E7
M5G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A9
M84AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+
M;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<31K059/=TA5
M-'$K)B-X03M'4'I4.#$O-' X*V%T<39.>G17;4U.:V4S,65(.3-'9CEK1C5F
M334P1VYX.$5!1VE2<W9B9BMC52].9C%J4CE4.')Z=E=3>&M&-5IQ)B-X03M4
M=C9-,W=Y<5!:2D%$.#-Z03=1>#!22G-G6'97835M-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ)B-X03LW1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ=U X-R].;BM'+WDU,4]E3BM&-69,.5%S+TAN8T%H
M:5!D66<W1#-'6D=L>#A5=WAK840U)B-X03LS.'!F;&,R<V9L1#5L.#!'3W0U
M87EP2G!V:C96;T,Q,&9K>5-(-E5Z6C5-+T1L15=!:G-K9C51*V)0.$%#+S5G
M859Q56HX3$]35#9R)B-X03MF16MH9E%N*T)M86Y:0U$O,%I:<6-F2$%H1512
M9F-'84)U9&ER<U9E065F+T%->5!Z,SAT6#)R6&<P;4=0>3-B6&MS5G!F4&)H
M>#9")B-X03ML2U%--5=3;S5$:G513GHW-7-S3T1$24%8-FU"2D1%.4LO-7E&
M+T]45C=R-G!P5FQB,SDQ>$PK:&)78VLP;D9E<F-56FI15GDV5VIX)B-X03M2
M1FLQ.%=);54S+S57<"]Z:VPO,4LX+R]!2$-R<DLO>2M$*V0Y<65+4T9V9GHK
M+T]V46%.<FUG=S(V>54T9EAB1S5T>#%0,E1Z:G)8)B-X03M*1%(T<&-J.7$X
M4EHS*UA(+T]2*VEE6DPK1%-.8W12<$=P6$)#5S@T9FYB4WE(8FI69W)2<W@K
M>4152"MA=$UX.#)I35)9,T-23S-S)B-X03ME64Q.>$E!<61G3W!X5C1J*UE0
M+T%$:S%O=6IZ>39F-5=T,#%I.&I*5C<V4FE,3E="+UDT,&%B=G5#;SA#8WHX
M3VA-=#5B341.:&UM)B-X03MF;40O04TU3&5:06(W4F]*:%I3,6%*;W)',U=!
M:710,V-L=VI&<68V>'DK5TA"2%DO96DU1E=F.#10>C4X;3-#>2MB9$Q.,5EU
M>7%Z)B-X03M85G%S2V(W.%DW:3)#4CAY4$AL.'-(-6)$4#93=D52>E185'8K
M8VU,+U9V4#)J5V1R6G@R9FPR.&MT-V$X:FYO,'EY>F9!-VE5141I)B-X03MJ
M=4MB8F=D<3!%2F%%0T)**W!E4&0W,W$X;"]&<$XW2G V0U<O4T-6<E--.4=M
M0T5X<61X,6%N9DYD1W(S-4YJ-7<X>2]N2BMF9FQH)B-X03M96#$W4S=A=U,T
M2D5,>5<Y5EER,4A*6D=&9F).<$1465HX:F)76D5)9GDW*V5F-3,K6DQT-U11
M<D,Q=C=I3F95:U-+,DY&6'!6;4UG)B-X03M59E-C33E*:&E,2G!226PY1"M3
M-W)Z2&1E5CE0=5!-;'5T<G)K:44S<T-!2T9B;7='=UIX.6UN9DYB;$5223A0
M2FU(961,<GI(82M6)B-X03LY47503&1U=#%R:V%!,E5$9TU'8FUO3WA:0CEM
M=F9(14EM431U4VPX-V599GHT+T]Z>3=F0W<Q=7AT8D,W2T-2635R66IK:'%!
M>6M/)B-X03M1=W%#2V<Y8S)C3DII:TQ"=')-:4=C9FQ4-3@O3VIZ3')M;3-'
M<V%82$@U5G5H2UIR-5E04W%"0S=2<VA:*U)6<$%O<49O8W@Y4FEX)B-X03M2
M0F\K<&Q%:W999%@Q8E1D2# R-#%053=H3%=W=$5-;'AC4T=I<6\K5S5*3W=!
M,THR1RM935EM4F]C,F(U-#AY+W=$3U,O;6Y73E,O)B-X03M29FM44VEG:TI3
M0U=323-.,TME>%-&86]U,S=*1#5S-&%'35)C>3%M9F-H6E!.2"]!1&Q81F),
M9$YB6'!I2C)29%!T2&LW.5EL:4UG)B-X03LV94=(=SE.*T-6.5-V-60O-7EL
M,2MY13EP-7 P<$QI94M.,6IM='=92F985E1X13!B17)2;F]'2SAE23=(<&=N
M;T%D-&Q24'9:.2M1)B-X03MV-7%A,34U='18:3%O44,X,#DT5VE-0RMN>6EM
M1$0W2DQF6F%0<C<U:C9V5&I(5F1755I7.5AZ1%I/>%8R2W9L-R]N2TAZ4$IQ
M;FTW)B-X03M4+TLY;U1)=6U2:#59,39T9%A60T8Y-E(X2V8V>'IB84-&4DUJ
M,6$U;F\K9W9*9FQ7,CAV*U,Y33AU<VEV2&$R;VEU5BLP<GE3071/)B-X03MD
M*WIY3WAZ5S5C;D9->5IG4&EN>GHU86PX<RMB=%8P3G<S1WEU2%-&;49#,$HK
M2THV9C558DMC,S)+9DA%1G!);W9S2#AN9DYN*THO)B-X03MY.3!Q+VMF;F51
M4B]5-S1K:VXQ<F-"0WI%.3-8:2\P-7!.5&HT2FM.,%196G!L0UA9<7<O.#,P
M4B]W07-F36]D47=&:DEW0D9D,3-")B-X03LK9VEU6#9B*SA(=E),:RME4"MC
M668O2FTO=T12:&-F<E1.;'(O=T,W*TQ81&TK=#@P>F%P6&1N85AL<DQA6&-+
M6$9R3W!384-6439/)B-X03MR8D975G%G9S114TYW<C1:+TUV>3-"-5HX*V%Z
M;S%R=&$R='=487)Y-499<$9%<V%L<6YD5F-$>'IF-$HX8T%3,%-&1CEI+VQL
M<E9Z)B-X03MR9FM$4614=7EZ,U4Y<$=*-4I0=%!*1U!49'HO04LU6&PY3V%4
M4$52;5%'-&-N:U O3U,O-6XS3G,S*T-.2FTY37E2<DIR8WEB3G=C)B-X03MC
M;S=A=EE-=$AF>$)!-F-H;6)O8T8K<R]":$]84DQ0*V-D=GEG<V18:"]X9#5G
M=#%U3$I(2V%66GEI<V-J>&UJ>D]P,EI666-60C)*)B-X03MR6&]-;G)D4U(V
M62]&65(V=G!C04%51W=(45IQ;7A3=7)3,79,85,Q=315=4QA6E-K,$5Q:#0S
M53E66E="0D(Y.$E*2$I8>4@K96XU)B-X03M8>"M34$U%1CEP2W-U:&%K4SEO
M2VMM,VU1,65(;#%P=4=1;F5M,B]%;DYZ<$TO:5)O.'<Q4VI4-G$X;C8V;78K
M5F1*,6Q756TO=%EP)B-X03MP94@R5FM:0C9I+S=&-G)M;WE1-%I%9'IA2&U8
M+T]624@O2W5R3#(Q5T=N+T%%:GHU;#9$*S@K1$-F2FIN+T])=C)03EAZ<U K
M>&I,)B-X03ME,&8T9FHK:$=..40U<D=X,DMV;F(O;DQL14@K1G!!;S5T.655
M=E1C9V96>4)8,G%C,F9:,SA8=V$X:C)R.'9F*U5".'1F.$%B2W-F)B-X03LK
M;UI-=TTS,6XS;&U/5'E,+VY,4%9R,D12+TPK;'AU5G1,,F$T;G5%2#=45WEX
M:4]V<U!78DTS<RM)<VQH:TM0+W=#8U9T33!.9DHY)B-X03LY<55%871R16PR
M.$8U37=(<4Q%<4DP8V$W,31'=DPS4"MQ36IR-4AI039*:'EE,C5G33-N+W=#
M83,U439(-34P,E-623!T4$U-2VLR)B-X03ME;V=53$5$84ME;3=X;G!8<795
M9'=C;E0V:S1Z+U)9>6IB=WHO;DAU-W9F3&8U=5!O96]21T,T=31R:E0W;4M1
M,#E/5TPY.$\Y0V55)B-X03M016908DYH<D%*67)$0T=X9E=E85IT9&EQ1S%4
M56)85$Y.=3E3=3(T5W1L1$IC5'0T2D5P9&IV5'--35EK;6=R-5 X07EF<TQR
M>C,K)B-X03MC>#%Y+UAM:T4X=7-89F=R2SE9149A-TQ+>55(9TTS1W!0:#1Q
M2'5A;S=L.6,U<&TQ.# O.#57959043%84R].14-5:G9%3FQE34)T)B-X03LV
M<U98:4HY,E%S4&MU8EAS+TIS671E44M(+T],6&Y'2%0Y6#%4>3=E>G)&83-S
M479,6G!'-'%*;V9H8T%N66,T>E4Q+VMW-B]&645G)B-X03MU379O0V9Z-S5'
M='IX;CAX85A%,U-J,W1U<"]&.#%O>%1042]*;F%/,&IZ0F]/<W!*2F\K<%=U
M<$I#47-R,FLX8S11;F-":D=Z57(W)B-X03LU1U5$2&U+5&%19FTW+S5,3'I,
M+T%-=T5V-G-S,#,Y-%!E:5A*.'IF.#0K83EO,F@O;4(Y93%I.&ES8E V;E!(
M-CAZ0E8U355O=%0S)B-X03M.33)U<V=:46]D-U9!-W9P;B]L8G8U6F8Y5$Q9
M9CAJ4FUQ+TQ:3S1T=D5%;3AX+VXO=T1L<&\Y;$Q,0G%A-G!D<7198D]Z1$]8
M8G-0)B-X03M5<#9A:GAQ,S!(<&QK3DAK:V5624UG*UA98E!Z3"M:2&YQ-&$P
M9SE853E8=4=N;$,X=E-G4FTS3$UE4E=/2F%$9G1T,7IB6$A&1&9K)B-X03M'
M<FU8,GHU9C!A,C!44710,&4R2F%$5#=E2S)J8V=!<TEK0SAI0C-A;%1M:&Y,
M:4I093-V:&)Z:G)5=74K8DY7,652:51F6&-S<6-I)B-X03M4>%)N4'!R53EL
M4VEJ,GIO355E1TE$465B-VTX<C9*1F]F;'943DAI0VAB0S)I9TI5541-:4%-
M,RMY87!/841*3&EK5#-T-%1024LW)B-X03M&56<X.&539$8X-39!*VDV=C9I
M,C=32DUK,$I66EDS:E R:TQ+-F=L4WDW<61I8W-X6E1#5FA"1F]J>6PU6# S
M>70U9G1D0S!X<%=S)B-X03MR34]):D\S3B]W0C0U:V%R04PK,'@W64UM47IL
M6E5"-6PO>FQ4+S5,;7DO-V%S2"]!0UEN>DPP2#DU.$=-*U1(4"MC4F9S96%V
M;EEF)B-X03LY:D=7.6\O=R](.4--8C9(>E=.:G-69E!(+T]86#)02W9Z=B]!
M4'-8>EHY;F9X9D0Y3%AK93!F;#DO>6=8;'(O04Q:5FPO,41P;4)M)B-X03LK
M<RLX<WAY67@K95@U8EA(;F9Y<6DV8T9/=&%9-U0R0W-E26Q6:%-72&M44E,T
M04E*-W%"<T-4;#)L>BM(3&9K55-&:#AQ*UAV3E!N)B-X03M,>4QR57HV8E!.
M<&0O1V93=DQ35DM"=4Y2=VUH:T9$4W V:6\W57IB>GAW>41F8TY12D0R6'DS
M+T%--5EY07!(-6PP44U++TAD86,Y)B-X03M#0C=15$4Q+S5':DU'9EHO.# O
M3FU-:C%4>70K9$@U8RM:1VIH<W174S-V2DM5<S=W1S-K-44P0V=V.$%U,UDK
M0TUC>$UM;6Y(;4=9)B-X03MK0VUS,S5E951*=DY!.#!Z85A(2G)W2T58<DTU
M26%-0E592GDY4&M!0CA81W511V%81'<S<W1-:7EP3'-695 O05!/5&9M>CE%
M*U)O)B-X03LY1VAF:F1A-TPV5$%D9G$X0D5K<#8Y,C1,.&EC>F1$:G5D.7I#
M6C)59BMC6'9+=C9..&U83W5Z2E,T,7%B.3!33B]Q.753:64K.&AC)B-X03LO
M9&@Q*U,U,3-,06)-=CA!4#,U=RM44$I984,O=51D87%"5F1-=&%03G5+<C9H
M<49J2%0W4G)4;T1L3TA45'EC=51)>4%E165C4% S)B-X03LU:V9M;G P,6Y:
M84Q(82M8;S(Y8TM&-4U41E5J.2]*5&MW-F9U,4AV;',Y5'!T3$U#8R]796XW
M0GE(=F)-96YY6D)C4C98:CEU64)C)B-X03M21S1$3F(X,3E925%(2U8K3&E3
M0T%A9$YS,CAR;S%Z8U5693<V;C!0+VY(8CAT-3=3,W5X1E!F5S@V3$Q&23@X
M:6@P9%%64#=V,#EI)B-X03M$6$]:+T\V<VUI45!H+V$U.&]9:'E$,%!Y5BM8
M+VQR>61$9'AA1F)',6IV1U(U:TUK:V],24-!45I'8VIR-#5--4UK+W).;'!L
M6%%))B-X03M8.#-F+TI:95IF.$%M06PO5FQU;2]V0C<R1754-58O2G)Y4F\O
M;E!Z:BMH=%=E84\P*W)3>CAR9&Q2*U5:541D;&-5*TQW>F-A;DM9)B-X03M2
M<TY54EI:3BMD6#5'>"M43%,S,6Y16'5,<E)$4TLK.6-Q.&M%<%!W35-I;U!4
M971/;7ID+VE'53985CA:<5A.36\P;'8U2#9&*U=V)B-X03MM3%=Z;S-M=4=B
M.4E3;FQP<$5Z4G=4,"LQ0R]#:DLK,59O=S5D3W1+>C%5.&M28V53>$%,-G4X
M="M5=DQF;'%Z3FYO5VY1,D5$53E4)B-X03LP;"M.>71A1U-2<74U1F1I>$]A
M965356I:3G1G0V):0DPX.3E3=%HW2%9,<3%N0E-E,6YE2U9E-&%.>7 O15HP
M:U198V-V=C=3=%)G)B-X03LQ3%,W4%5B8S%T-S)#3S1H4"M22V=D9G=B3V-K
M2TY/46ES0W5X5C)+=7A6-#,O>FQ4+S5,;7DO-V%S2"]!0UEN>D\P2#DU.$=%
M*U1()B-X03M0*V-29G-E879N668Y:D=7.6\O=R](.4--8C9(>E=.:G-69E!(
M+T]86#)02W9Z=B]!4'-8>EHY;F9X9D0Y3%AK93!F;#DO>6=8;'(O)B-X03M!
M3%I6;"\Q1'!M0FTK<RLX<WAY4D=Q*V(O3$=K-FQ:-EAQ3W!W5S)P6#=);'!:
M=30Y5GI),T)#14970W-W;T=/,6-%8V-I3$$R0S)H)B-X03LO3E!K2'ED-7%2
M5C$W4V]B,3!(1DIY0VMY9U8R5U=-<$E"=C U57<T.#!O9E-6270U3C5I+W=#
M8U5D0FY":SAV-G9C5U5M-3E#-U9B)B-X03MI36YS07EE:WE$-3AS>DED;U-(
M,4)I64(U2C4P+TDO.'=02V--;#-D5V$S,FY21&Q*9E=,1U9%1DMK=7!#>4E"
M,UER>#DX>F-7<6A0)B-X03MB<7=-0T4X+TIB.#9.6CAU87A:-DQR1C(Y>C5B
M=5A70VMZ8VIA1GE&5U-.:G5),5 R;#95<5%+-5AQ=$M*0W@Y4UEY9E<K85IT
M9&ER)B-X03LU0R]/+U<W<GIL*V),85!92#%%<S59.4ES:S9!>F,K37!0.$%Z
M,EEI=F=";38P<V5$2%HY-U9,8W-R.#EF;D\R;3)6<#5"+TQ9;#%S)B-X03LT
M:W-',6%%5F0R4F5"5S)P,TY+;5AX<G@O;7I(:F=!0GDU5%$U-R]P6FEY94=0
M3D)E4G9Y8U0Q;#%$>D@O<"MP4TXV:E<W2&Y':DYU)B-X03M42518,5@X93-Z
M-C5Y;F%0=$AK>FYW.4XV669Z=7 Y,V0Y+W5D,W!U>EDT>'A:9#5D,U0Y<C-8
M4E!,8U5-841G049!04%&04%/9T=9)B-X03LR:C=/-FYM:E4V,V](>4PK8DAL
M9B]$6#5G87AP:7)X='973GAA539E:D]05E%$+U8U8V9O>C!$4WHT<UE,;UHX
M,S!H+WIJ:#5T+U1F)B-X03LU97A713!N2SDP3GI:=4-A=#9"*TM"=FQX<6<O
M,6,Q;71X.$TW-S)Y0C)E<5II36U)+VTW+W=#4WDX>2\X=T5V-G-U,#,Y-%!E
M:5A*)B-X03LX-V8X-'<O*U1.+S9-3&HY85IS.68O9"]&<FAZ9E=';U=&;G%.
M:E!9,W-+,T9N9%)T1F-1=4MQ-D]+340Y1V%C16<R1S$X6"]!2G$O)B-X03ML
M,7%8-64K86=L=3AH,#)D:F-A3F9G:U!X4F=E0F1A9G99:E-P2',R,6,S=6YZ
M1$I(>C9T36A4-DDO22\X,F\O3W5J;E0Y4V16.'EA)B-X03ME9RMS:EEF5TEH
M.$EN5F9(;TA!-DAF;V%$5V%R5"M'8D@P;'-J2S-P*UEJ2CAH+S@U1BM2<#E!
M.#A4879$2%13.65*=5DS1S17-3(K)B-X03MS269C=695+S)7,U$U=71&;#1O
M5C%$5DUB=E50*V-B9GI+=$Y5,$=0>6IQ13185G1-0D9G2$\X.7)U=U935'4P
M3S0T+WE5<#!A;4IR)B-X03MC0D5U26-I>6=8=&U91$XR2W-*+TY(.#!D1SAI
M84TP,'I*4')--D@Y2&%D6#1N8G!Z96TV>'%E<#<Y0G9L*T1!8V@X:T4P<R]*
M,WIL)B-X03LU:S@S955).5<Q,G=3>FQ-:E)W5'AK:&)L13)-;VI.4V<U9D0Q
M3E-$4V=W-FY&1T5Q0E=*<TI*+WIK<G!&>'%(-5E45%%G;CE',V-&)B-X03LU
M26\V;%!I:% S9715*S)784=66E!E:5DR95=F.#1S*UIR9E0O3G5O84QC4W)%
M=7-7-FTS1&9T>C)Z17%G4&E9-4A0,%IL-BM&>$(W)B-X03MM1TUV<69.43)U
M>%8X<B\X-4IA,FYM3#AW9$\X=F%5=W4U9%!15W)*2#A8*VU836YX4FEM>$E(
M04AW3E(R>F(V2U!$07E05G%N=6%F)B-X03M4,FMA9DAP=6Q75VY2<UAJ<V])
M<F1(26]3<U-"06%F-TA.5$DR8F)8>G0O>FQH<&I7*W0K6&1B:5ER3$Y"3&)C
M;#)+;3)K5U9$6'AR)B-X03M/9G5Z6CEN>7-%3F,S<78U4&9M9%IE95!,:V)3
M>4MU=C)A2VUQ5S)W2EEB0V1&1E!G:S8W1#14=#16=SE49T]/6&MY:6):.6U/
M>6-1)B-X03M#2TAC2'%-5F9#4&YA>7-J*UE7<S)E:7AQ,7%D4VUI<V]904-H
M0FU+<6M96&)J6%IA6C!/26YG0E!C,$AM*S=S-35V4TQZ,35L:CAS)B-X03LK
M54Y7,3$V8W)',UHT45)51UIV9VA5*WI336]Y>D9$:FM!9VUN=VEK.3=,94=6
M2&0W=61M0EIA;#-A5V]B<'53,TQ/9TY!8CAG,&EY)B-X03MD;G9V-5DO;#%(
M;U9S;'AC;TI.8756+V50,3E&1"]U=%0O>$DY.#AY-V(W66QR8VYH-"\W;V8W
M3'I0-D$Y5&]D1TU%94M8,6XW4$HW)B-X03M8;T]I<$5I<U)V,T]:9EHR:$51
M-%=S,5)*43,U;"MA=%,X<&552CE9,'5Y5R]U-%I):U<R64]14DDT56UI9D9S
M339,5%E22UA#9&Y6)B-X03M3:V5B-4LX+RM94$](;F98+W="3F%N<&)W>D-&
M3&5/1S-G;%9&:FI*24AX8VU*3$U456Y.,VAH2$A'9U=K,E94.'8X07I2-34X
M:F%U)B-X03LK;S9265-V-C9E;&17<SA%<E)3<%=O<48T:T94,$E0-$4T33!)
M6D)22VEW*W5F>34X>F%J-6XX;39F<FUO,F=S8GDW.6(Q8E91=T-E)B-X03ML
M3SA3-U X049U<4$W-7!S,$)#4D$S8E%8:5@U=B]N=F58;'(U:3AL5W5I;3-:
M8FEB5#5.4DUX:S52=WI&2$MX0TYA96]%+VU.2S5N)B-X03LV8E-!151*65-L
M,&559FQX-7EV=DI0;7$S,3)'>DXR<V%34E0R<$IJ.5-/4F%%8RM,8U-$43E/
M,EIM9D=-:V%T:$4P*W5F>78O340O)B-X03M!0C$U9&PQ;CE(='!V<%A4,G8Q
M9'!05G)W4D@U.'5%9E@Q2V1/,F%84&@X3U988F-$84XX*RM39$LX-2M7-VI2
M9%%(2&XK.'1B:T-R)B-X03M1>G%$=VM8-59O4C-"27=98W!H2W=P1G9J3V$P
M.#-F;"]W0V-3<3@W3%<Y2FTO9'I)0U9)<'-Y,49(:FM1.7A1<60X,VQX>5(X
M:3 W)B-X03MG=F\O.'!0>C%V.$%Z<')-96A8*VER85AA,GIZ>E@P57)'2FUJ
M2VEI=W-L5G)Y+S,T8S%E;S!G9TQ"8DEY=#9.-74X<&%,-7,P1S0P)B-X03M8
M5TEF5G1:>%985V=K:6M8-T5S8D5(:38O=T)H<4-2;4QJ>4="<TUI3&9+2&Y8
M.&QF4#A!-4HQ1#8Y65)Z6#EH8G8V=')Q,6='.5-0)B-X03MG95%A4D5*:VE:
M859R.6YW8DYX:3%536=O-TAU86I%:$]V3#,O3U0O04HW,'DS4S(Q5S)T=%A%
M93-R>6AO6GIT44)M:BM!,"\Q2RM*)B-X03MY13E"03AT:VE:4F5O9CA!3U-V
M-6HV-G<P-WDU<%5.<&14,%=-,CAC;#5C.'$O-W)$5E1F,VI/4D=H>'@S:U4X
M6E!*3E!)4"]!1&HY)B-X03LU:C$O5D(U:B]-8658:DEY>7194WE&-W%E9T90
M6&5P.4Y+54A%2&PR*TA)-71:1TDT8V%I4&4K:DE)24QE0T\S=#0Q:&=H55)X
M4E)G)B-X03M+:4EO;W%Q;V]!04)105IQ>6)B1FPU6C)T-UIZ,F0S1W,Q<F-X
M=D100S(V=DA)<%9L4'-185E184YH6'EJ*UDS-4)E8E!+,F]T<6YL)B-X03MM
M3V)5.4E75#%B9#=B:S$S8E502E$V2CA2-#EN5'=Q94]B:D)R27I&4S),5DM&
M8VQB>3<O04TU3RME=$IT57-T5W1,9E8O4DA%5'IC)B-X03MO8F<P,DA.;"M&
M<54O:W%E-7=4,$U$=4YL17EU,6XO;DE4.'IV3F@O4DAL>7A&:$IC07%&,#5*
M2C=X:'@K24LK+TAX<6E":#0T>#!E)B-X03M/1SAJ.#$T>6543U!Y4B]);3@P
M4RMJ.# K83!8.4MP5G10,#AK4V5I>D%G>E1%5D)K,RM%8CAE=C)V<S0K<3%9
M:T]'4$IL1TPS5$YE)B-X03MZ95!F.#5284\Q-2M8<T8W1D9Z;# V*VED,T<U
M5TM66&EB-S-:37ID0DMP,3-H:$UB4$<Y3R]+,S@P9$(P3%(O4%!L=U1.3%!&
M.5E-)B-X03MD;GDK=%%+>D5*>6DS.5=/5U!I,G=/>$E953-/9$Q5635%=VMX
M-%-.,E=A3"]W035795ER2T@V=G(R:'<S,7A'07!M:&MA,&-L9&E8)B-X03M2
M:VU8:V8X04I#:C)Y;5A:.%0Y2E1X<&(U;R\U>4@X*RMB:T]I*UA.3T]M<F55
M:C179D\U=E@U0VA22D96859R*W=G8C-Y95!2=VAV)B-X03M),F=Z2C5-<B])
M+SAH<C=48BM$>E0U<V@Y1S9T>4I.3C!T<49K:S9R3DXQ05IE<7(Q0C-.0TM:
M5'%T5T-/1TM9>&911V$Q<V5"9CA!)B-X03M/5G9M;C!D3#!R>7A#.4I,='IF
M6&%J+V955E5I0CEM8W-F.$%9-7-E>CAE-6MW;5AN4#5,*U5L=3=Y5'I"9'!Y
M9W1'.4]Y53=G>E5Q)B-X03MZ+S=!2&(S4'1M:3ER3S O1&=-140V<#=Y+W$Y
M,W@K-S-U,C=(,'9%9D5026-V92MI+TQ7;6,R17)$8R]Q>FTK>71*935C-UA:
M-C):)B-X03MR1D=),$-J3W1H2&A&3V=L2WEV>6)&,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+;T,K.'9A0G%%=G$S*VTR=#-+3VMK.$5C:F1!)B-X03M/
M<G%4,GE1;5)Y2V]I>G-,1WAH149L8E)7<TDV4E%O<V$O.$%!<4%-0DI03E9F
M07)S5F1I<G-644XO;T]H-FDT9E5.3W1B>#$K>3%X)B-X03M$2$M2.&DT3U-%
M>4]25EAS-T-X<UE20EI7,%9R0T]K54M,1W8O07%!34)*4$Y69D%R<U9D:7)S
M5E%6+V]E:6%I>71Q1VXR,31Y+UI.)B-X03MX1$A+4CAU64]316E/4E96<V1.
M,#=4-'92<TQ71S!I+S,S0D=S82M04D%",W='4E!.55)G5C)+=FE0.$%/2'I1
M,VUN.'AT579)5SE7)B-X03LQ:6Q&;%E5,T)I9RM!1F$O>G1Y9C9C,S)N:'=9
M>&9V85IB;#=J-5$P1DY+,&94.4I10W-%86E5:G9)9FEK8C972GIY5%=A9S9R
M57EN)B-X03LO3VPY;E0W2',X5TU98U%J,T(V>&]T<4EO1DY/,F1B;TU01$8U
M-U9:3&LX<C@Y+VY6-3 X<2MA6#!75'DY8G-K>C$P>59P4U=N:%IY)B-X03MK
M8B]!4T%7239(9DYI-&%J969N=C5Y.'98=&]03B]L1G)#>'5I44I),UE/471/
M4E1L5D=+,2MZ56901EAS36PY2DYO>E@R;&],<5=7)B-X03LS33EJ1U-&5U9M
M5&Q%3U))041B8C1&94]A4BMD+VXW55!.-BM6:#5A=&AQ:51.1&110V9D0D5F
M,W@U1G5"-'%#9&TS-UE693 S=#=A)B-X03LR3FY093-C<7<R='1',',X>C=+
M:4E/5$UF:T)G5C0S2"ME9FTW>DIQ;'IB95$O3$@V471B46-P3&DU66=L9#9%
M9TY':6-Q9D-P8VLT)B-X03M65%AY2"ME0S9X-6=B>7HU;# P-DQR=DUX4DQ5
M*VTX;R]W0C%%34]33V8R9'E$-#E+:%AP1W0V>%IA3'!&-7$Q.'A7,'-O;6UM
M2VER)B-X03MC549A2TYQ:SE"-S1Q.&=S+W=!-E!Z3#%E,FXQ=E$O2C8S9FPR
M0U)L3&5O>E1K2G4Q3TIQ5%1R>&I.4&9#<DY0>6XO36AV4%=K,S$S)B-X03M.
M87):6$YN8VU%,C9-6"]D<V]A3FE30G5F:4A4=&=66"]-<CAZ3DDX:39:1E!D
M4G1D,SDP5U=Y<U592U@T+V%:,DYE2T-O<6%(-5EQ)B-X03MW069N3BMA<U=J
M9C1I=69*<UHP07 V:7IQ,&ES15E65U$Q3'1W-SAU1E!F0W(P>CAV4$XV*V)V
M2U9L<FYP<D1.4'I3-&=1:VA*23-+)B-X03M%5E!Y0BMN07)Z-SAW+WIP.#,K
M55!--S942F].=3EV3CAE;E1.35,P,%)B:4A)46YI95%);V%(0W(Q5'DW9&$Q
M9&%,83-'=#)A-F9Q)B-X03MK:6LS5FUJ<DES6C5%04(Q3$$O1%$Y8T-V261D
M+U!$>B]P4&UP=DQC=FQI,T]O=DE&=$E"35AA4EI$*S9)2T9L<7<W5G=Q<7DO
M;F8U)B-X03LS,&96.4YT+TYF;%ID23 K.6U33U,W9'!+2VI-03=+>'%P2T0T
M<5EQ.64Q;695-$Y*=35T3'1L=DY2:FE:<E,Q9&=I>5-!9D-H6FEO)B-X03M7
M<#=K-$9E3"M89BMC:DY2=5!.;'1O;79A5$)P.$5L=V)3-FU34FDP36Q39W)8
M-&%#4V=B,C-W<6UT:BMA+S5J5"ME:#53;#AS5S98)B-X03MS8DLY,&]U05-L
M<5-P86)L>31':4]$44@R-C1Q>C=Z,34T,&9Y8F]4-G1Q4EHV=#9D=&)2,#E3
M855G:TMT96Y3<%!99F1G5C5L<#,U)B-X03MY+VUP<61G*W4V9C5-4S0P0D-Z
M1C!E47E-:45H=4160F5L1%5R1V-+<S8O2VXX=VHU-#AV>C9J3&)P85A6=F-T
M8GDR.&)&9T%&5C!A)B-X03MP;V1W,S191EDO.$%M="MA,VUV>5!Q8TMX-DI$
M8V%28W%"8E@P:W!"855#<VEC54I+.&$Y>'9I<5(S=C4P9FUL6393=7-86&MX
M63E-)B-X03M:1FM&,WEK2V-(1E99;&$P56<Y5&A6-C$U5#AW4659=DQE;F$S
M04%Q6#!#>7-G3F5$.4I%<B]K3T-V,%E&964K62]Z:C$K6'IF8V56)B-X03MF
M2D=H:E=.47-/679:6FTT;T=J64LT54)K*T9'255S>D1F86YI<70X;R]N3G(K
M;V5E8E1Y;#5I,$ID1W9*:VM%<%IN-4=656%23TMS)B-X03M+8T=69'1Z6'-C
M5E1N.#5V>DAS4$M(;$\X4TLU56$Y97AT0G Y=7)$,59A445E=59R54Q'3G=F
M1V=Z2C R07IL-4U:1VYY2C533F]0)B-X03M.1VQ'.%E*8D,W:$UJ3CEK04]$
M.%AT6')M=S=3-"]Y,E1G*W)G;%AY5'!A.%=..')$-GDP0TE3,UE98F=!55!Z
M>GEJ<S=(95(V>E9Z)B-X03MQ1#!7,E%,0V]Z=6-586DX=FM.;#@X+S@U1TQC
M3BM99FQX8EIG;'=B94E1=7=Q<75B;'5*23A!8W592F(K8C)L9FU&<#%X<$XO
M=T-F)B-X03MB,D189$=79&QH=&)*>&)B,$1/<'!#:%5S1BLQ4G9M359F4FYL
M>E5,2%5V3"MM,RMN;UDW1S9T;W!B84DW1DDR44954%AD4G1G5C1&)B-X03LU
M32\Y85@Q3"]M2S%$+VLR*T98<5 U-FDX4#5783),6&,P9TUT2SAV4T9X1UAP
M5#(V*S%C0W-D+S5X:DYL+V=7.4526#8P3E%K*W-G)B-X03MF87 V569#=G13
M=%!P.3A664@K94A"+WIN,#5D2S,Q1&I9<DIW<'DK=&5Q9E0V8C$T96YH5C=T
M*UI5=6AX*U)D64]U0UDV53!(0S5.)B-X03MU;V550U(Q4E=116=65C)",W=+
M.$4P6'E(*V%U:#9B1G)V:TA65S%(4G)X0F-29E9:1E9Y4$-A,&Q*47E,4VI+
M=DQF8D-R3B\K8V90)B-X03M..$]Q,W5U5TXQ<&M.;')J1F)Q*W4T16%-,T)$
M<W)'5TUN:6IO.&XW3D)U9&AI<D50*V-J+U5J+T%$2#!Q82M6;C P5V-"5F8R
M4VEZ)B-X03MY1U92-RM0,%EQ*VM96'-R>7A2-'5%,6IC4D)K24%-8GA/=%)T
M,$ML5&=6:C,U9C(O:V%Z,'$V<V9*.'-B,DYT9%-,9$I(23AV1S0R)B-X03M6
M-BMO5TY0:$9+9D-E,DMV1V8X06Y*3"]!2E0W>2\X03AW<V8O55,K1E@P9&=6
M.#)F;7)&<6MV-3DV8D9P37E7*W!0.5-&;E!+3U-*)B-X03M+9G-S=V\Q440W
M6594+WDQ6E%A1F](;D,X+TY'>4YZ0V18:FUD-4E323=Q87!54U=Y<TEG-FMK
M:V-D=4YC5F4Q-EIE5SDW<#%R95=Y)B-X03ML8F$U:&IL9U9L-$52=6]:87(K
M>G-E;4)8>3%0-4HO>$)P9FXO56)A4&QQ5VEA<SEX2%%B=$%8;3ED4'554#A!
M-T@S=W%N,S5)95DW)B-X03MZ>D0K878V479F:75X;R\Q96%1;7!D;T)&1GI0
M=7=512LK2V\O=T0U>7%3-C4K6$@S*W%!6%$O>6954'!D9F9J,'=+.6PX:3-/
M;C-0)B-X03MK>E)*=$\T+U4R<V]"145P4F5-655R=#-69U%F9D951#50=%!)
M3FIQ*W4R;FQP-%8Q17II6%=R94M2,C1Y='E)*T)I5E5$:U)23F=D)B-X03MJ
M=4U6961F.#549CAC1%$O*UEU6"]K,VEQ1#AL-D(U=E1Z<F\K;V5B0W0Y;T(X
M=6Q)-S%):71N1&%016%15%!W4D$O16YL53=G.6-+)B-X03MV52]Y,S%N>6YQ
M=FQM3U1Y<F%T86%08GEV0D9#,%AO+T5T1UEG5E!+=D]V2W98<G9G5C1J<6YK
M=6)Z3C4S,3-79GDV,58W6%8W3S=K)B-X03MA+S K-&,R;'=S>D]F5FMT-45,
M8S0R:W)8;'AP.3)&5G5I96(O3G5L9FU,;V5N+VU,<&$S="]&2DA"6EAK-DM,
M;4):,S1,2DA,0V5%)B-X03MY0B\U=5AE:$)R:7)W6$]L8V0R2W9:9BMC67%F
M-'$Q3W8O3$EV+TIW6F]U,U!P:"]7+U$U=6HO:3EZ-G)J*W=0;&U*2&LQ>35V
M:VHX)B-X03LV9CA!1C,O2WE,:CE*979Y.54O;TQP+W9.-G)E:C901"]+*VUU
M5%%G3EDO>%8K;4Y-+S578BMM4#!8>C(Y6&PV;D-O-2ML-G9W5CAE)B-X03LK
M2W9Q,692+W=34#A-53E,.4<O-VA05#95.40O045B:GHO,E R=G!W2RM5=DMV
M.$%J=CA!-5=H2#9(<B]!3THO<F(O6"]S97 Y;R]7)B-X03ME5F9H*WAY<BM'
M1E@Q.7$S-DXO4F0U*VLO5"]2=F]Y9EAF5B]U+U(T;C%/9&8R94YA-$9F2FUM
M+W W+T4K<&8X<6LO4S,V3F]057 Q)B-X03LT,5!(;BMZ>"]K-2]&4W9V:%9K
M=C5)+S1D+W@O3B]I-S8S+VI0,4<K<698<3A06#,U.'58>"MV5#=03&)W,W!I
M<C(O.# O<78O2W5F)B-X03M-9C%N*S<K;U1C854O=D]0-W9R+T%-5V-C0W9M
M6'EH+WES:C9Q+SA!9TPY3"]63T,O6"]3+W5F<D9">C15*T0U9G15=W$Y6"]!
M3V-B)B-X03M0.$\O5F18-"MV.$$T<S5J.4PO5W9T8T]48V94-S U5C4X=FDU
M9&4R0E4T+S5Y1B]W5"]H4T@O14AQ9G!(;3,V1RMR8V98.5-G-2]A)B-X03LR
M.4PW4$]V=%1E;4MV0V1/+W=#5FTO-&)I<BMM=CA(,2]E+U9V5SE(,&$O2'@O
M6C1F4#1A-%9F5%@U568T32]W6F%F-%)R*VIA=#9V)B-X03MQ9C,O04LK,W%E
M=B]!2F8T57!486U"6'HQ*V5V*THO*U9I,T@V4SE4,'%J.4,Q-"\W>CAV:#E0
M:B]L,38W-%9F4W9K1"]%6"M$.4TO)B-X03MX2GHO044S-F)F6&96-#@K6'%.
M>#5C4&@K>%1!<C57.#4O-#@O=T-6:GEF6%!R6"M)+W)!+U(S2"LO-#AZ.5@Y
M3# O8C=.34MQ5W8O)B-X03M!3TYF,'AP6"]+=V8P;CE1.5I++UAV5B]U96$K
M=#984#1E6$AR5#)X5CEA*V%F,' O:$Q59CA09CAD3#9O+S9-.4AJ+T%(;D0Y
M,W=R)B-X03LX2'DW649E02]K0B]J1"]'*V\K=C8S-DHU5&8T:CE8:G<Y9FA*
M=SE8;'9Y-3AU;C T5EAF:V0K:5 K5GIA="MH<2]O<C!B>C9J>38K)B-X03MJ
M-GEC4&]P,'A6-C<K8V8K1% X04)&>B]!27(U+U4K42MQ96A4-G@Y6F]E2&]6
M,C5D974Q2S$R=TLK879,,R]+>E P3F1F-&$O5% K)B-X03M(9E50<F95=E<T
M57(X5E!4,C55*S-X*VYB0W(V12])<B]!+RM&-5 X3BMR.6,U:CE-+U<V9E<O
M6' O=7EM,T1R=W!T,3<Q=TLX>"\U)B-X03MY62]X3"]I5S(K<RMR+V@W,#$K
M;U9P-EAR.&8S=$MB.'5N6$-R0W19+W=#5G,O-%II+U-V-E@O=S4V8UAP*W0V
M,S%B,'5).4MV-U!')B-X03ML2U9X5CE,+T%*3"]!2TXO-59J;U V4"]!3'(P
M1SEA=$LK=C9J9797;B]&=DMN=%1!<C4Y.'HO6&8K5G K678X3&98=CA1+W!+
M5#9J)B-X03LK:B\Y6G9R6%!H.%@R+V\V.'-+<'8U42MU+SA!2S Y3"]W0U9P
M+U@O04Y*9G4O,$XY87 V6'$X>C904"]!0U!5*WIX,C4O83<T<2\O)B-X03LR
M43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M8FYA
M:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C
M<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @
M('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C
M(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HV,#A$-D5#
M1D%#13%%.3$Q03-!0T5#0S%&1C(Q.#!$.#PO>&UP34TZ26YS=&%N8V5)1#X*
M(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HV,#A$-D5#1D%#
M13%%.3$Q03-!0T5#0S%&1C(Q.#!$.#PO>&UP34TZ1&]C=6UE;G1)1#X*(" @
M(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T
M.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O8W5M
M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT
M/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E<FEV
M961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HU1CA$-D5#1D%#13%%.3$Q03-!
M0T5#0S%&1C(Q.#!$.#PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HU1CA$-D5#1D%#13%%.3$Q03-!
M0T5#0S%&1C(Q.#!$.#PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @
M/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"1D1"
M,3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT240^
M"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT/"]S
M=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I=F5D
M1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS
M879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C5%.$0V14-&04-%,44Y,3%!,T%#14-#,49&
M,C$X,$0X/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#$Y+3 Y+3(X5#$P.C0T.C,Q*S U.C,P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R
M94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S
M=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C
M=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP
M+FEI9#HV,#A$-D5#1D%#13%%.3$Q03-!0T5#0S%&1C(Q.#!$.#PO<W1%=G0Z
M:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C Q
M.2TP.2TR.%0Q,#HT-3HR."LP-3HS,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T<F%T
M;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E
M<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C
M<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*
M(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA9&]B
M92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU<W1R871O
M<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U<%!R
M;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!4
M4&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @(" @
M(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM
M<%109SI(87-6:7-I8FQE3W9E<G!R:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES
M:6)L94]V97)P<FEN=#X*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE5')A
M;G-P87)E;F-Y/E1R=64\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y
M/@H@(" @(" @(" \>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@
M(" @(" @(" \>&UP5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T1&EM.G<^-3DU+C(X,#(W,SPO<W1$
M:6TZ=SX*(" @(" @(" @(" @/'-T1&EM.F@^.#0Q+C@X.38T.#PO<W1$:6TZ
M:#X*(" @(" @(" @(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET
M/@H@(" @(" @(" \+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM
M<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L
M86-K/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!44&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'
M<F]U<',^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \
M<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @
M(" @(" @/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X
M;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4
M>7!E/C \+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @(" \>&UP
M1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z4V5Q/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y7:&ET93PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3
M/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP
M,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @
M(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D)L86-K/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P,"XP
M,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TS-2!9/3@U($L],#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XS
M-2XP,# P,#0\+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z>65L;&]W/C@U+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @
M(" @(" @(" \+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y'
M<F%Y<SPO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.F=R;W5P5'EP93XQ/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @(" @
M(" @/'AM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @2STQ,# \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 P+C P,# P,#PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L].3 \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^.#DN.3DY-# U/"]X;7!'.F)L
M86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" @(" @(" @(" \
M+WAM<$<Z0V]L;W)A;G1S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'
M<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F
M.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C
M97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO
M>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E
M;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0'_P  1" "$ 9 # 1$  A$! Q$!_\0 '@   @,  P$! 0
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M0K.%$TP'^CRY$J,YPBLQ\E!8_4 33..M?Q&R\3,HBXB)2.E6Y1\17C7K9\B
MCW[ *K554@"/8?D)N_R'AT>,X=&0^3J5/U$ T!!Z'/LKD>0THXI1Q2CBE'%*
M.*4<4HXI41=\]FH[3O3_ #[L6]5:E?XZH$HXJ+9WX"A)Y"G#(UO'<2JF;N*B
M$E=9B":O (10R;%1TX],Y$3!R]\.:0^NZYINE*#RW=RBS%<Y2VCS+=.".A2W
MCD9>GI #.]2;B40PR29P54\N?I'9![V(%9K/3HUQEMXM]<%8@G_?+!'7K)1;
MAEB0=G5<+O*+65'5ZR4ZD7IQ$2.YV%BY.+;O'!A]6;F&*8@JLX(DIUAQ3JJ<
M.\-ZC?1<L3VUIW%DJX 6XE MK0(OBL<CHY4=(XV.P!(QRWC[Z>-#DAFR_7=1
MZ39/K (SYFF./:K-54R,M<]PZU%)I)LO>]>LB+-&Y2$3:F+*77%CA1- H%21
M;F)D.+<.EB^!17@&!%"_X.D;5?8UK/I:KH4KD\W+J=J"?G#DM[P#/4L#:N%'
MT96QU-7'5(MHY@.GQ;?:R?\ J'U"DWXF5DH*4C9N&?.8R7AI!G*Q4DR5,@\C
MY*/<)NV+YHN00.BY:.D4ET%2"!DU4R'*(" <WNZ)(CQR*'CD5D=&&59'!5E8
M'J&!((\0:LX.-QL1N"/"M9/1+9>-W!U#P%L8P4;&>9(Q]$O;4V:>(-XR_P .
M*M<R'#I$+_(0BKM$3S%KY%3,HT006],A52E#BOB/27T/7-2TI@>6TNG6$MG+
MVTF);5SGQ>WDC8[G<D9K*H)>^ACD\649]3#9A_B!J6O++4ZCBE'%*.*4I/U;
MM5.MSE+=&]W?22P[&,-?'52Q^WKS+&VV\+B>MA,QU58-;0+*BN\S4UTS='F4
MW)G;CX @,DX$[I-5T"H*GW7P3K/9]9Z!;V_$,6E/J8GN3(UWHCWLO=O,3#S7
M(L)PRA".4=Z>0;8&,5:;N*]:9F@,G=X7'+,$&<#/H\Z^/JW]=+'YAVJZJ.O^
M1K)B3-&U>[^.<CU!RBUL-2LNQ>9FDDP.Y;(OF2Y1)=U6KUA(,7+9_&2D>X=1
MLFP<-WK!VY:KI+'V[8Z-P;J=K%?6&B\.W5I."T4\6E:>R-@E6&]N"K(P*NC!
M71@590P(JVO+=1L4>6=6'4&1\_M>/4'H1TKB:#N)U1LJS2U;Q?M)OMDBQ-X]
M>77@*#FO82X32$4U7:M7,FM%5ZRR+Y./;N7K)NN].@5LDN[:I**E4<)%/'<Z
M%P=91B:\T;AJTB+!!+<Z?I<$9<@D('EA12Q"L0N<D*2!L:+-=,<++<,>N%DD
M)QYX!KV+Z>]<7]L>JQ_;VW/_ 'KE!\'[._[#@O\ V6A_\M1<][]*Z_Q2_P :
M/I[UQ?VQZK']O;<_]ZX^#]G?]AP7_LM#_P"6G/>_2NO\4O\ &NLRV\W5WP0N
MV<7;9'>BB'%4"-D\KW++_NJJH=S D5EDA9TS7'L41]$4% $ 'N00[\FIP[P/
MJ09;?2N';G;TO@4%CS >?-:88>W(]M0]]=Q]9)U_+9__ %'_ .]31UT]I-ZB
MV'Y:.)E:=I&R]-1523D(2_U2$J=G&/*8!53AKOCR,KSAM)' !!.2L\-<DR>1
MA58..Q/"PZKV4<+7R,;*.XTF<@\LEM-)/#S>!DM[IY05\TAD@SX,*J(]2N$/
MIE91Y, #CU,N/K(:G,NG9U0=;^I#1'TWB=^\JV2*JU:K9%PO;5FA+I4?>#E0
M)*LE&QO=+53W3P?=V%JB"E3 ZC9K.1\!+."Q1=#<4<(:KPI<K'>JLUK,S"UO
MX QMY\;\C9&89PN[0OOC)C:5!SU=[>ZCN5RNS#',AZCUCZ2YV!^L G%6/\Q6
MJFCBE'%*HJZE?7@UJT.>S.*Z,U2V#V1CP5:OZ%7)A)E3L>OQ*)2DR9<T$7Y&
M4JW./JJ4N!:25C_-"WG#55-VRD%=B\)]G&K<2+'>W#?<S2FPR7,L9:>Z7._P
M2 E2R'I\(D9(M\Q]]AE%#<W\<!**.\D'50<*I_&;S_%&3X'EZTG)LCUH.I3M
MY/+13[.MPQ] 3KPK&)Q7KP,IC:'-[\J"2,(1>LNCWVV%=*'31*SL]IL1G"@E
M322*!@2YO72N >$]#C#KIT%U+&O,]YJG)=OZ(R9,3#X-!RX)YH88L=2=LU9Y
M;RXF."Y4'YD>5'LV/,?82?*O@H71RZKNPB);C'ZJ99=?%RE=&FLNS]6QI+O4
MU@!0CM5OF*V52P.B+%,"B:WN:OK$,"B8G*8##%<\=\%Z7_5VUFR7D]$1V,4U
MW&I&W*#8P31+C&,<PQC%%L[J3<1-[7*H3_C*FNQ3W2:ZP^J7JWR&UYSM4G,8
M7WL;%@.]PESL#8C?\Y[T1+!MWL5G1*W HJ&5%HF*)2BH;P*43!*CXUX$UK%M
M)J>G3ASR]UJ=M)!$2=L$ZC;Q0[]/E;].NU>FTNXO2$<BGSC(8^7_ .FQ/_3U
M5)W3GVB/>S5JPM:9L4Y=[.XZBGWPJ>K^4#'ALQUTK584'Q8O(_N(S3R8:JE4
M%TSR,PM:BRB1F*;N%,<SM&T:[V7<.:Q$;C2@ND73KSQ2V?QEA+D97GM>;NUC
M8$8:U:$ 'FY9/DF9#J$\1Q(>]4;$/\L>>&ZY_*YO=7E^=NMKL??^H8.SF-\R
M; 4G7>'R_CNPUO7\F2;1"4][C.AN:XV>U^TX]@K0YI3MW>XZ&D7UN9&"3:NI
M&?D$1>N42(J!6:;V?:5:\+_<B[L-,N-5DL;J.74_@D,DZWER)2LD-U)"MPJV
MS.BP-Z!"1*>4$D5Y)>R-<=ZKR+&'4B/F(!5<;%0>7+8)/49/4BM'^'EHV?B8
MN=AGB$C#S4<REHJ0;']1L^C9)LD\8O&YP^1T'359)=(_^4F<H_?SE5T>-WCD
M4J\;,CJ>JNI*LI]8((-9$"" 1N#N#ZC4$>J-0=G,GZ+9QH^G#VX1^QTV&-_P
M=.Z#D)KBNV)?#<MT.6MGPJ^/+)46T%YTAC9$WWJ6&/\ B<<=W#D][4D",G.1
M\'W.D6G$>G7&NK ^E1FZ^%+<VIO(#SV-RD//;"*<R8N&A*XB;D?EDVY>84]T
MLK0.L/-WAY>7E;E/RU)]+*X]'.=^FU(T;-47K[Z=TD,D[#Y7WEHU *_91CFX
ML=N+7?*]&/9)4K:.2G)+'67[8A7R/W9TV+)><-'MW<@NW8-U5'CENBIT1I%S
MV::[<?!-+L>';BZY6<0-H<%M*ZH,N8UNK&$R\JY9A'S%5!8@*"19)1?PKS2/
M.JYQGOBP]Y5VQY;XWJ /Y0_?_P#SY-P/_J6S-_?3F3?Z+\,_]W="_P#I&G_^
MWJ1\(N/[>;_:O_S58=KEC'V@?;*B,<GX&R;O5;\>2RKM*'N$KMO::!!SGN#I
M9B\7@'>1<P5,)YFV?MW+!5]#E?,R/FKIH*_O#9=-/%]5O.S+1;EK/4K/AR"Z
M3E[R!-#AN9(^90RB46MA-W;%2&"R%6Y2&Q@C-1&NH3+SQO.RG."9BH.#@XYG
M&=]MO'(\*>ZZ>E.SYC_2_7ZF[1NK,]S_  %+59Y/=7*Z-\B6=:P&GIEP0\Q=
M6L[9F]A=?#5F  ]2GI(H(@DW]<!1%-/G+B>?3;K7M3GT=85TR6XYK-8+<VL(
MB[M!\7;F.(Q+S!O1,:>>-\U?+<2+#&)<]X >;F;F.<GJV3G;'B:F9RPU.J$'
M4AI.Q&1M)<^4K4]W:F.PL]7H!OC-W2;RVQK:491O=ZP]DS1%X=V"K-Z^L:NM
M9@BSA6?C0<-3+L054,Z*W6R'A2XTNUX@TVXUI86TN.64W:W%L;N$H;>94[RW
M6*8RCO6CP.Z?!PQ "Y$BY61H)%ASWA Y>5N4_*&<-D8VSXCRI#K9^K]>O36K
M-KUL;EO>J@TAU(-HKZ8M=K[G>:NSD7HB5BSEYW'F6;7&P2[]0HHL"33F/%\X
M#W=IZRX@F/1VD3=FVO3&VTJQX<N;@*7[AM$M[:9E7Y31QW5C \H4;MW8?E&[
M8&]6.47\(S(\ZC.,]ZS#/K*N0/?[*A/7][^H[;9Z%JU6W)W6LEFL<JP@Z]7H
M'87.,M-SDU*NDF,9$1$4PMR[Z2DY%ZNBT8L6:"SETY53002.H<I1R&7ASA6"
M.2:;0>'XH8D:26632].2..- 6=W=H J(J@LS,0% )) J2)[DD 33DDX $DA)
M)Z #.Y-,B=,+5GKO5O<;7?)FT4]M<IKA'SDV_P BQV5-L$K+%*0[NCV9I%DL
M>+);,<M87X%GW<.8L<[J+ATS>%1=JM4?=#K(ZIXOUGLXFT+5+31XM%&JO'&M
MJUGHAA<2+<0LYBO$L(XES$LGIK. RY )Y@#<+:*_$T;2F;N\Y8-+D8(.,H7)
MZXVQD=3BG..:%J\U#G=S>K7W0+#[G+^?+(JR;.EEXRETF#3;O[UD:Q)(>O\
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MP -R2>@ \2:5E-]2G:-WNIO)GS.;%PXDJY9KRO6L8H$!502XWIQ4JC02M6@
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MWKC;BBWX8T::;O%^Z-TDD&F09!=IV7'P@KU[FUYA+(QPI8)%D/*M2K2W:XE
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M52S'R &2?<!5BK7_ ,)8QA\*8;Q1AVOIHI0>*L;TG'<45 @)I"QIM;C:\W4
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M;*QJ[9\Q<I]Q\%VJZ2I.X^)PY,EBBGC:*:..:)QRO'*BR1NIZAD<%6!\B"*
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M=(X/J^9:.\^N'CXGVCVIZQ]S.%YK6-N6XU>5;!,'#"W_ -;=OCQ4Q)\'?_\
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M=I(^*KAHU7;$.45NX7GA[5Y-"UK3M6C!;X'<*\B#8R6[@Q7,0/0&2WDD0$[
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M8\IMTZ5V;[%9FS,TUBRS8DN]#D7!$Q7C;.^RA5:"Z!F<P>H"DG5;K8X@Y$C
M!BO064*8B'RV%V774]OQEIT4);DO(;ZWN5!.&A6SFN1S>&$FMXI-_HX&YJAU
M%0;5R>JLA7VEPI_W6-9R%-BIF=M]5A*X58]AF;)!Q4"1N!A7/,R$FU:1940)
M]<5C/ED 3 OUA.)0+\^W.J+AXXX)Y)<=U'#(\F>G=JC,^?5R@YK'@"2 .I(
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MWQ3+G01*80%54K"+?.13)W,"+=540\$S"$_M@1FX5A(&0FL6CL?)3;WJ9/\
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M<0^D/C),,_F-O13^Z,Y_&)\,5<[S ZK*.*5DQ[_XJ_ AN_MCBM-M[I'T_/\
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M45Q7+UTLG$GOM!5657;SJ]1D_?%8B+CW"GP2OSH3*YKBP9'E_A3)N1K,6,0
M< Y_C2K/E54D$SK+*)HI)E,=154Y4TTR% 3&.<YQ I"E !$QC"   "(CVYY2
MLRS!]EKL;U:<56^2GH>/JC+J$5&PO;,^DF;2 9P".Q+&06FW<PX63CVT0BP
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M5W^E&H?V-G_LYO\ W%8SW">;?6/X4?D[,*?M1E+^VZG_ '(X_P!*-0_L;/\
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M!S2E!/R>&%?VGRC_ &U4_P"Y/(N<^K[?XTH_)X85_:?*/]M5/^Y/'.?5]O\
M&E,-=!+4;%.#9G8[(%65LLO:Y*,Q[3B2EG>Q#Q6,KSIU9IN381GPN#AA13F)
M**A7$E[P9T"IH2,]$&_I+"OX6)ZTID'D-*6)F>DWJ;M/U']X?PL-LA.26* 4
MMC1.OVQI $JUSLIJ!(/[=7@:P1C*RR:[N5!%I9C6.OJ%F9 [^$>K@Q691!B
M /"E*CYTU]IF,=GI+"L#)V=W5F=H5A$G\N]BG%@,U(].V!11TRA6$<+CP* B
M<L45/S[B"0!]7D0<X)VVQ]M*?6Z7G3EUBTTQ=!Y$Q57)F6R=E&FQ#JU9+ODD
MRGK?\+D4FLHI585>/B82)@*R1\1%PJRB(AH[EE6K!6P/YA6,C5&D!8GK]7A2
#O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g918491g99y26.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g918491g99y26.jpg
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M@I&Q\!8S-V*AL\'1"5-S='5V@Y*TX20T0T145I2BPM/Q_]H # ,!  (1 Q$
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MV>VO4WY-_(_G?^<U'_%T.&F7\)P_FK^Q\5YYQ[XSC&?;.<9QC/\ U?\ S_\
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M!E)K,IT?.OAY:AXR7$@P3)<7V&F=&9CJ6*MJXY8<OR^B@ED?,*P,M*TT:%Q
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M4 /\]:PE#E=GM3LL-/:=/I?LYTNPKLYS^'.98?/'1"2"5'9>5W4%&9YI26L
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M/%(0)JB8@IXJH"DJK!"4AB5F$2M(2[-(0NY1T@IE+,0TK"S$=%'7:OV\D^I
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BX=GM)L1!^6+3:1P<"0+PFRSD(8\ 7N03<\_JYZ_\L&/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g934781g87f98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g934781g87f98.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1V(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '6R^=3(X0DE-! 0      #\< 5H  QLE1QP"   "(V < E  "')R,CDT
M,38U' (% !Y-:6-R;W-O9G0@5V]R9" M(&%R8W5S(',S+F1O8W@ .$))300E
M       0<%&9@1B TYP2_,R"66F<^CA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M         $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!7
MP           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C
M4FQT                4V-L(%5N=$8C4')C0%D            08W)O<%=H
M96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,
M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#
MO_XU  (  CA"24T$)@      #@             _@   .$))300-       $
M    >#A"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #-0    8              $@   #5          $
M                     0              U0   $@
M     0                         0     0       &YU;&P    "
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   $@     4F=H=&QO;F<
M  #5    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(
M   '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG
M:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y
M<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M 0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M        0G1O;6QO;F<   !(     %)G:'1L;VYG    U0    -U<FQ415A4
M     0       &YU;&Q415A4     0       $US9V5415A4     0
M!F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC
M96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(
M;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC
M959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%
M4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M    "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M      MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M     #A"24T$$0       0$ .$))3004       $    !#A"24T$#      3
M#0    $   "@    -@   >   &5    2\0 8  '_V/_M  Q!9&]B95]#30 "
M_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3
M%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-
M#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,_\  $0@ -@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\
M  $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M&K/VOJ%A< UC(=+WEWT?1Q69+_?]-]M"?CCQ2%[#4^047;_Q
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M<W:QMA@9<<$:)28U.#DZ14A25E=B8W=X@8>7M<+5\/_$ !T!  $$ P$!
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M*G114Z**G114Z**G114Z**_@ZA$R'44.5--,ACJ*',4A$R$ 3',<YA I2E*
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MX?:;I,E_HEO?P(9)-+F:1PN6/T2Y5(Y64#<A7C@D/8('8]*B=.E"3-&3@2*
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MF?(F(;]Z(" ]^P]=&VB_2_9XD<1YF;1>3 SCFC0EEVP>BG/D?,UK[DK?D_\
MBGL 2"<9\M\XR-\ Y[BNB(4Q3  E,!@,4#%$H@(&*/J!@$/00$/4! >PAV'\
MO7.%;!7GHHI2;DN7+DOG;T,QW73%>RM2/07LV5 04^'-Y"Q.I$ZCGP"/E@@U
MCE%5BF["0ABF,'8P=6]PO_U7@'B&XERJS?2!'G;F9(E4 9&#DL"#ON-M]JB[
MC+7L"^7*3MD@$DYZ[#;[\]*;(ES/2Q4F:-,4LB$>\,P,H3S"%>@V5%L)B#V
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MRGS# @@^H-:UUZUKK[QF$A^>'<6#_P"7U2_+\_\ >CK(^G7O_;+K_P Q-_\
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MTFZ*9CB1(@%:FGFN&#SS2SN%"AYI'D8*"2%#.6(4$D@9P"2<;FE  V  '7
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>?ZQ__&L1X^OQ"M7VRA^BXZ!T^;?B:<F^M^?(5__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
